



Clinical trial results:

A Phase 1/2a, observer-blind, randomized, controlled, two-stage, multi country study to evaluate the safety, reactogenicity, and immune response of the trivalent vaccine against invasive nontyphoidal Salmonella (iNTS) and Typhoid Fever in healthy European and African adults

Summary

EudraCT number	2021-005178-25
Trial protocol	BE
Global end of trial date	07 January 2025

Results information

Result version number	v1 (current)
This version publication date	07 January 2026
First version publication date	07 January 2026

Trial information

Trial identification

Sponsor protocol code	216152
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	79 New Oxford Street, London, WC1A1DG, United Kingdom, TW8 9GS
Public contact	GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 February 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 January 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and reactogenicity profile of GSK Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) vaccine in healthy European/African adults

Protection of trial subjects:

All study activities at the study center were performed by trained clinical staff authorized by the study Investigator. The attendance of the study participants to in-person study visit posed risks that do not extend the risks associated with clinic visits for routine immunization. Considering the measures taken to minimize possible risks to the participants in this study, the potential risks associated with the study interventions and study assessments were balanced by the potential benefits that were provided to the participants. Study participants were observed for a minimum of 60 minutes after the administration of study interventions with appropriate medical attention available in case of anaphylaxis.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 September 2022
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	5 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 50
Country: Number of subjects enrolled	Malawi: 105
Worldwide total number of subjects	155
EEA total number of subjects	50

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	155
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted in Europe and Africa.

Pre-assignment

Screening details:

Stage 1: Of the 51 participants enrolled, 1 withdrew after post-screening procedures before randomization and did not receive the study intervention. Stage 2: Of the 107 participants enrolled, 2 withdrew after post-screening procedures before randomization and did not receive the study intervention

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Stage 1: iNTS-TCV low dose group

Arm description:

European participants were randomized to receive 3 doses of Invasive nontyphoidal Salmonella (iNTS)-Typhoid conjugate vaccine (TCV) low dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Arm type	Experimental
Investigational medicinal product name	Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses per participant

Investigational medicinal product name	iNTS-TCV low dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses per participant

Arm title	Stage 1: iNTS-GMMA + TCV low dose group
------------------	---

Arm description:

European participants were randomized to receive 3 doses of iNTS-Generalized modules for membrane antigens (GMMA) low dose vaccine and 3 doses of TCV low dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Arm type	Experimental
Investigational medicinal product name	TCV low dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:	
3 doses per participant	
Investigational medicinal product name	iNTS-GMMA low dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Arm title	Stage 1: iNTS-TCV full dose group
Arm description:	
European participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Arm type	Experimental
Investigational medicinal product name	Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Investigational medicinal product name	iNTS-TCV full dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for suspension for injection, Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Arm title	Stage 1: iNTS-GMMA + TCV full dose group
Arm description:	
European participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Arm type	Experimental
Investigational medicinal product name	TCV full dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Investigational medicinal product name	iNTS-GMMA full dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Arm title	Stage 1: Placebo group
Arm description:	
European participants were randomized to receive 3 doses of Placebo and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Investigational medicinal product name	Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Arm title	Stage 2: iNTS-TCV full dose group
Arm description:	
African participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Arm type	Placebo
Investigational medicinal product name	iNTS-TCV full dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Investigational medicinal product name	Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Arm title	Stage 2: iNTS-GMMA + TCV full dose group
Arm description:	
African participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Arm type	Experimental
Investigational medicinal product name	iNTS-GMMA full dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
3 doses per participant	
Investigational medicinal product name	TCV full dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses per participant

Arm title	Stage 2: Control group
------------------	------------------------

Arm description:

African participants were randomized to receive MENVEO as comparator and 1 dose of saline on Day 1, BOOSTRIX as comparator and 1 dose of saline on Day 57 and TYPHIM VI as comparator and 1 dose of saline on Day 169.

Arm type	Active comparator
Investigational medicinal product name	Menveo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose per participant

Investigational medicinal product name	Saline
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses per participant

Investigational medicinal product name	Typhim Vi
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose per participant

Investigational medicinal product name	Boostrix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose per participant

Number of subjects in period 1	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group
Started	4	4	16
Completed	4	4	14
Not completed	0	0	2
Consent withdrawn by subject	-	-	2
Not specified	-	-	-

Number of subjects in period 1	Stage 1: iNTS-GMMA + TCV full dose group	Stage 1: Placebo group	Stage 2: iNTS-TCV full dose group
Started	16	10	45
Completed	15	10	45
Not completed	1	0	0
Consent withdrawn by subject	1	-	-
Not specified	-	-	-

Number of subjects in period 1	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group
Started	45	15
Completed	43	15
Not completed	2	0
Consent withdrawn by subject	1	-
Not specified	1	-

Baseline characteristics

Reporting groups

Reporting group title	Stage 1: iNTS-TCV low dose group
Reporting group description: European participants were randomized to receive 3 doses of Invasive nontyphoidal Salmonella (iNTS)-Typhoid conjugate vaccine (TCV) low dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: iNTS-GMMA + TCV low dose group
Reporting group description: European participants were randomized to receive 3 doses of iNTS-Generalized modules for membrane antigens (GMMA) low dose vaccine and 3 doses of TCV low dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: iNTS-TCV full dose group
Reporting group description: European participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: iNTS-GMMA + TCV full dose group
Reporting group description: European participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: Placebo group
Reporting group description: European participants were randomized to receive 3 doses of Placebo and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 2: iNTS-TCV full dose group
Reporting group description: African participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 2: iNTS-GMMA + TCV full dose group
Reporting group description: African participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 2: Control group
Reporting group description: African participants were randomized to receive MENVEO as comparator and 1 dose of saline on Day 1, BOOSTRIX as comparator and 1 dose of saline on Day 57 and TYPHIM VI as comparator and 1 dose of saline on Day 169.	

Reporting group values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group
Number of subjects	4	4	16
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	4	4	16

From 65-84 years	0	0	0
85 years and over	0	0	0

Age Continuous Units: Years arithmetic mean standard deviation	21.8 ± 2.5	35.8 ± 12.0	36.8 ± 11.1
Sex: Female, Male Units: Participants			
Female	4	1	11
Male	0	3	5
Race/Ethnicity, Customized Units: Subjects			
Black or African American	0	0	0
White	4	4	15
American Indian or Alaska Native	0	0	0
Other	0	0	1

Reporting group values	Stage 1: iNTS-GMMA + TCV full dose group	Stage 1: Placebo group	Stage 2: iNTS-TCV full dose group
Number of subjects	16	10	45
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	16	10	45
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: Years arithmetic mean standard deviation	33.1 ± 11.3	34.7 ± 9.5	28.2 ± 6.3
Sex: Female, Male Units: Participants			
Female	10	10	26
Male	6	0	19
Race/Ethnicity, Customized Units: Subjects			
Black or African American	0	0	45
White	16	9	0
American Indian or Alaska Native	0	0	0
Other	0	1	0

Reporting group values	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	Total
Number of subjects	45	15	155

Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	45	15	155
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	28.5	29.7	
standard deviation	± 6.3	± 9.1	-
Sex: Female, Male Units: Participants			
Female	23	5	90
Male	22	10	65
Race/Ethnicity, Customized Units: Subjects			
Black or African American	45	14	104
White	0	0	48
American Indian or Alaska Native	0	1	1
Other	0	0	2

End points

End points reporting groups

Reporting group title	Stage 1: iNTS-TCV low dose group
Reporting group description: European participants were randomized to receive 3 doses of Invasive nontyphoidal Salmonella (iNTS)-Typhoid conjugate vaccine (TCV) low dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: iNTS-GMMA + TCV low dose group
Reporting group description: European participants were randomized to receive 3 doses of iNTS-Generalized modules for membrane antigens (GMMA) low dose vaccine and 3 doses of TCV low dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: iNTS-TCV full dose group
Reporting group description: European participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: iNTS-GMMA + TCV full dose group
Reporting group description: European participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 1: Placebo group
Reporting group description: European participants were randomized to receive 3 doses of Placebo and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 2: iNTS-TCV full dose group
Reporting group description: African participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 2: iNTS-GMMA + TCV full dose group
Reporting group description: African participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.	
Reporting group title	Stage 2: Control group
Reporting group description: African participants were randomized to receive MENVEO as comparator and 1 dose of saline on Day 1, BOOSTRIX as comparator and 1 dose of saline on Day 57 and TYPHIM VI as comparator and 1 dose of saline on Day 169.	

Primary: Stage 1: Number of participants with any solicited administration site events after the first study intervention administration

End point title	Stage 1: Number of participants with any solicited administration site events after the first study intervention administration ^{[1][2]}
End point description: The solicited administration site events included redness (erythema), pain, and swelling. Data for solicited administration site events is presented for each intervention administered in each arm group. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received first dose of the study intervention and who had solicited safety data in the 7 days following first intervention.	
End point type	Primary
End point timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants				
Redness, iNTS-TCV low dose	1	0	0	0
Redness, Saline	0	0	0	0
Redness, iNTS-GMMA low dose	0	0	0	0
Redness, TCV low dose	0	0	0	0
Redness, iNTS-TCV full dose	0	0	4	0
Redness, iNTS-GMMA full dose	0	0	0	5
Redness, TCV full dose	0	0	0	0
Redness, Placebo	0	0	0	0
Pain, iNTS-TCV low dose	4	0	0	0
Pain, saline	0	0	1	0
Pain, iNTS-GMMA low dose	0	4	0	0
Pain, TCV low dose	0	1	0	0
Pain, iNTS-TCV full dose	0	0	16	0
Pain, iNTS-GMMA full dose	0	0	0	16
Pain, TCV full dose	0	0	0	1
Pain, Placebo	0	0	0	0
Swelling, iNTS-TCV Low	1	0	0	0
Swelling, saline	0	0	0	0
Swelling, TCV low dose	0	0	0	0
Swelling, iNTS-GMMA low dose	0	1	0	0
Swelling, iNTS-TCV full dose	0	0	4	0
Swelling, TCV full dose	0	0	0	0
Swelling, iNTS-GMMA full dose	0	0	0	3
Swelling, Placebo	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Redness, iNTS-TCV low dose	0			
Redness, Saline	0			
Redness, iNTS-GMMA low dose	0			
Redness, TCV low dose	0			
Redness, iNTS-TCV full dose	0			
Redness, iNTS-GMMA full dose	0			

Redness, TCV full dose	0			
Redness, Placebo	0			
Pain, iNTS-TCV low dose	0			
Pain, saline	3			
Pain, iNTS-GMMA low dose	0			
Pain, TCV low dose	0			
Pain, iNTS-TCV full dose	0			
Pain, iNTS-GMMA full dose	0			
Pain, TCV full dose	0			
Pain, Placebo	3			
Swelling, iNTS-TCV Low	0			
Swelling, saline	0			
Swelling, TCV low dose	0			
Swelling, iNTS-GMMA low dose	0			
Swelling, iNTS-TCV full dose	0			
Swelling, TCV full dose	0			
Swelling, iNTS-GMMA full dose	0			
Swelling, Placebo	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any solicited administration site events after the second study intervention administration

End point title	Stage 1: Number of participants with any solicited administration site events after the second study intervention administration ^[3] ^[4]
-----------------	--

End point description:

The solicited administration site events included redness (Erythema), pain and swelling. Data for solicited administration site events is presented for each intervention administered in each arm group. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received second dose of the study intervention and who had solicited safety data in the 7 days following second intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	15	15
Units: Participants				
Redness, iNTS-TCV low dose	0	0	0	0
Redness, Saline	0	0	0	0
Redness, iNTS-GMMA low dose	0	0	0	0
Redness, TCV low dose	0	0	0	0
Redness, iNTS-TCV full dose	0	0	6	0
Redness, iNTS-GMMA full dose	0	0	0	3
Redness, TCV full dose	0	0	0	0
Redness, Placebo	0	0	0	0
Pain, iNTS-TCV low dose	4	0	0	0
Pain, saline	2	0	0	0
Pain, iNTS-GMMA low dose	0	4	0	0
Pain, TCV low dose	0	1	0	0
Pain, iNTS-TCV full dose	0	0	15	0
Pain, iNTS-GMMA full dose	0	0	0	14
Pain, TCV full dose	0	0	0	7
Pain, Placebo	0	0	0	0
Swelling, iNTS-TCV Low dose	0	0	0	0
Swelling, saline	0	0	0	0
Swelling, TCV low dose	0	0	0	0
Swelling, iNTS-GMMA low dose	0	0	0	0
Swelling, iNTS-TCV full dose	0	0	2	0
Swelling, TCV full dose	0	0	0	0
Swelling, iNTS-GMMA full dose	0	0	0	1
Swelling, Placebo	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Redness, iNTS-TCV low dose	0			
Redness, Saline	0			
Redness, iNTS-GMMA low dose	0			
Redness, TCV low dose	0			
Redness, iNTS-TCV full dose	0			
Redness, iNTS-GMMA full dose	0			
Redness, TCV full dose	0			
Redness, Placebo	0			
Pain, iNTS-TCV low dose	0			
Pain, saline	2			
Pain, iNTS-GMMA low dose	0			
Pain, TCV low dose	0			
Pain, iNTS-TCV full dose	0			
Pain, iNTS-GMMA full dose	0			

Pain, TCV full dose	0			
Pain, Placebo	5			
Swelling, iNTS-TCV Low dose	0			
Swelling, saline	0			
Swelling, TCV low dose	0			
Swelling, iNTS-GMMA low dose	0			
Swelling, iNTS-TCV full dose	0			
Swelling, TCV full dose	0			
Swelling, iNTS-GMMA full dose	0			
Swelling, Placebo	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any solicited administration site events after the third study intervention administration

End point title	Stage 1: Number of participants with any solicited administration site events after the third study intervention administration ^{[5][6]}
-----------------	---

End point description:

The solicited administration site events included redness (Erythema), pain and swelling. Data for solicited administration site events is presented for each intervention administered in each arm group. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received third dose of the study intervention and who had solicited safety data in the 7 days following third intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	13	14
Units: Participants				
Redness, iNTS-TCV low dose	0	0	0	0
Redness, Saline	0	0	0	0
Redness, iNTS-GMMA low dose	0	0	0	0
Redness, TCV low dose	0	0	0	0
Redness, iNTS-TCV full dose	0	0	3	0
Redness, iNTS-GMMA full dose	0	0	0	4
Redness, TCV full dose	0	0	0	4

Redness, Placebo	0	0	0	0
Pain, iNTS-TCV low dose	4	0	0	0
Pain, saline	1	0	1	0
Pain, iNTS-GMMA low dose	0	3	0	0
Pain, TCV low dose	0	0	0	0
Pain, iNTS-TCV full dose	0	0	11	0
Pain, iNTS-GMMA full dose	0	0	0	14
Pain, TCV full dose	0	0	0	2
Pain, Placebo	0	0	0	0
Swelling, iNTS-TCV Low	0	0	0	0
Swelling, saline	0	0	0	0
Swelling, TCV low dose	0	0	0	0
Swelling, iNTS-GMMA low dose	0	0	0	0
Swelling, iNTS-TCV full dose	0	0	2	0
Swelling, TCV full dose	0	0	0	0
Swelling, iNTS-GMMA full dose	0	0	0	1
Swelling, Placebo	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Redness, iNTS-TCV low dose	0			
Redness, Saline	0			
Redness, iNTS-GMMA low dose	0			
Redness, TCV low dose	0			
Redness, iNTS-TCV full dose	0			
Redness, iNTS-GMMA full dose	0			
Redness, TCV full dose	0			
Redness, Placebo	0			
Pain, iNTS-TCV low dose	0			
Pain, saline	1			
Pain, iNTS-GMMA low dose	0			
Pain, TCV low dose	0			
Pain, iNTS-TCV full dose	0			
Pain, iNTS-GMMA full dose	0			
Pain, TCV full dose	0			
Pain, Placebo	5			
Swelling, iNTS-TCV Low	0			
Swelling, saline	0			
Swelling, TCV low dose	0			
Swelling, iNTS-GMMA low dose	0			
Swelling, iNTS-TCV full dose	0			
Swelling, TCV full dose	0			
Swelling, iNTS-GMMA full dose	0			
Swelling, Placebo	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any solicited systemic events after the first study intervention administration

End point title	Stage 1: Number of participants with any solicited systemic events after the first study intervention administration ^{[7][8]}
-----------------	--

End point description:

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain) and fever (pyrexia). Fever is defined as body temperature equal to or above (\geq) 38.0 degrees Celsius ($^{\circ}\text{C}$). The preferred location for measuring temperature is the axilla. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received first dose of the study intervention and who had solicited safety data in the 7 days following first intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants				
Arthralgia	0	1	3	3
Fatigue	2	3	7	11
Headache	3	2	6	5
Myalgia	4	2	6	6
Fever	0	0	1	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Arthralgia	0			

Fatigue	2			
Headache	1			
Myalgia	0			
Fever	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any solicited systemic events after the second study intervention administration

End point title	Stage 1: Number of participants with any solicited systemic events after the second study intervention administration ^[9] ^[10]
-----------------	--

End point description:

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain) and fever (pyrexia). Fever is defined as body temperature equal to or above (\geq) 38.0 degrees Celsius ($^{\circ}\text{C}$). The preferred location for measuring temperature is the axilla. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received second dose of the study intervention and who had solicited safety data in the 7 days following second intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	15	15
Units: Participants				
Arthralgia	1	0	1	2
Fatigue	2	1	7	6
Headache	1	1	5	6
Myalgia	2	0	4	4
Fever	0	1	2	1

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			

Units: Participants				
Arthralgia	0			
Fatigue	1			
Headache	0			
Myalgia	1			
Fever	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any solicited systemic events after the third study intervention administration

End point title	Stage 1: Number of participants with any solicited systemic events after the third study intervention administration ^{[11][12]}
-----------------	--

End point description:

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain) and fever (pyrexia). Fever is defined as body temperature equal to or above (\geq) 38.0 degrees Celsius ($^{\circ}\text{C}$). The preferred location for measuring temperature is the axilla. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received third dose of the study intervention and who had solicited safety data in the 7 days following third intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	13	14
Units: Participants				
Arthralgia	0	1	1	2
Fatigue	0	1	4	7
Headache	0	1	3	7
Myalgia	1	1	5	10
Fever	0	0	1	1

End point values	Stage 1: Placebo group			
------------------	------------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Arthralgia	0			
Fatigue	0			
Headache	3			
Myalgia	0			
Fever	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any unsolicited adverse events (AE) after the first study intervention administration

End point title	Stage 1: Number of participants with any unsolicited adverse events (AE) after the first study intervention administration ^{[13][14]}
-----------------	--

End point description:

An unsolicited AE is an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the unsolicited safety set, which included all participants who received the first dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints.

End point type	Primary
----------------	---------

End point timeframe:

Within 28 days post vaccination (day of administration and 27 subsequent days post-first vaccination on Day 1)

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants	4	2	14	13

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants	4			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any unsolicited AEs after the second study intervention administration

End point title	Stage 1: Number of participants with any unsolicited AEs after the second study intervention administration ^{[15][16]}
-----------------	---

End point description:

An unsolicited AE is an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the unsolicited safety set, which included all participants who received the second dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints.

End point type	Primary
----------------	---------

End point timeframe:

Within 28 days post vaccination (day of administration and 27 subsequent days post-second vaccination on Day 57)

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	15	15
Units: Participants	3	1	8	8

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants	2			

Statistical analyses

Primary: Stage 1: Number of participants with any unsolicited AEs after the third study intervention administration

End point title	Stage 1: Number of participants with any unsolicited AEs after the third study intervention administration ^{[17][18]}
-----------------	--

End point description:

An unsolicited AE is an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the unsolicited safety set, which included all participants who received the third dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 28 days post vaccination (day of administration and 27 subsequent days post-third vaccination on Day 169)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	13	14
Units: Participants	0	1	3	5

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants	5			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of participants with any Serious AEs (SAEs)

End point title	Stage 1: Number of participants with any Serious AEs
-----------------	--

End point description:

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. Any = occurrence

of the event regardless of intensity grade. The analysis was performed on the exposed set, which included all participants who received at least 1 dose of the study intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants	0	0	0	1

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants with any AEs/SAEs Leading to Withdrawal from the Study

End point title	Stage 1: Number of Participants with any AEs/SAEs Leading to Withdrawal from the Study ^{[21][22]}
-----------------	--

End point description:

A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was

performed.

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants with any AEs/SAEs Leading to Withholding Further Study Intervention Administration

End point title	Stage 1: Number of Participants with any AEs/SAEs Leading to Withholding Further Study Intervention Administration ^[23] ^[24]
-----------------	--

End point description:

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. AEs/SAEs that lead to withholding of the study intervention administration were considered under this outcome measure. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants	0	0	1	1

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 8

End point title	Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 8 ^[25] ^[26]
-----------------	--

End point description:

Assessed hepatic laboratory parameters included alanine aminotransferase [ALT] and aspartate aminotransferase [AST], and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 8 (7 days after the first study intervention administration) compared to Baseline (Day 1)

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants				
ALT Below (baseline) - below (Day 8)	0	0	0	0

AST Below (baseline) - below (Day 8)	0	0	0	0
Creatinine Below (baseline) - below (Day 8)	0	0	0	0
Urea Nitrogen Below (baseline) - below (Day 8)	0	0	0	0
Basophils Below (baseline) - below (Day 8)	0	0	0	0
Eosinophils Below (baseline) - below (Day 8)	0	0	0	0
Hemoglobin Below (baseline) - below (Day 8)	0	0	0	0
Lymphocytes Below (baseline) - below (Day 8)	0	0	0	0
Monocytes Below (baseline) - below (Day 8)	0	0	0	0
Neutrophils Below (baseline) - below (Day 8)	0	0	0	0
Platelets Below (baseline) - below (Day 8)	0	0	0	0
WBC Below (baseline) - below (Day 8)	0	2	0	0
ALT Within (baseline) - below (Day 8)	0	0	0	0
AST Within (baseline) - below (Day 8)	0	0	0	0
Creatinine Within (baseline) - below (Day 8)	0	0	0	0
Urea Nitrogen Within (baseline) - below (Day 8)	0	0	0	0
Basophils Within (baseline) - below (Day 8)	0	0	0	0
Eosinophils Within (baseline) - below (Day 8)	0	0	0	0
Hemoglobin Within (baseline) - below (Day 8)	0	0	0	0
Lymphocytes Within (baseline) - below (Day 8)	0	0	0	0
Monocytes Within (baseline) - below (Day 8)	0	0	0	0
Neutrophils Within (baseline) - below (Day 8)	0	0	0	0
Platelets Within (baseline) - below (Day 8)	0	0	0	0
WBC Within (baseline) - below (Day 8)	0	0	0	0
ALT Above (baseline) - below (Day 8)	0	0	0	0
AST Above (baseline) - below (Day 8)	0	0	0	0
Creatinine Above (baseline) - below (Day 8)	0	0	0	0
Urea Nitrogen Above (baseline) - below (Day 8)	0	0	0	0
Basophils Above (baseline) - below (Day 8)	0	0	0	0
Eosinophils Above (baseline) - below (Day 8)	0	0	0	0
Hemoglobin Above (baseline) - below (Day 8)	0	0	0	0
Lymphocytes Above (baseline) - below (Day 8)	0	0	0	0
Monocytes Above (baseline) - below (Day 8)	0	0	0	0
Neutrophils Above (baseline) - below (Day 8)	0	0	0	0
Platelets Above (baseline) - below (Day 8)	0	0	0	0

WBC Above (baseline) - below (Day 8)	0	0	0	0
ALT Below (baseline) - within (Day 8)	0	0	0	0
AST Below (baseline) - within (Day 8)	0	0	0	0
Creatinine Below (baseline) - within (Day 8)	0	0	0	0
Urea Nitrogen Below (baseline) - within (Day 8)	0	0	1	1
Basophils Below (baseline) - within (Day 8)	0	0	0	0
Eosinophils Below (baseline) - within (Day 8)	0	0	0	0
Hemoglobin Below (baseline) - within (Day 8)	0	0	0	0
Lymphocytes Below (baseline) - within (Day 8)	0	0	0	0
Monocytes Below (baseline) - within (Day 8)	0	0	0	0
Neutrophils Below (baseline) - within (Day 8)	0	0	0	0
Platelets Below (baseline) - within (Day 8)	0	1	0	0
WBC Below (baseline) - within (Day 8)	1	0	0	0
ALT Within (baseline) - within (Day 8)	4	4	13	16
AST Within (baseline) - within (Day 8)	3	4	14	16
Creatinine Within (baseline) - within (Day 8)	2	3	14	13
Urea Nitrogen Within (baseline) - within (Day 8)	4	4	15	15
Basophils Within (baseline) - within (Day 8)	4	4	16	16
Eosinophils Within (baseline) - within (Day 8)	4	4	15	16
Hemoglobin Within (baseline) - within (Day 8)	4	4	16	16
Lymphocytes Within (baseline) - within (Day 8)	4	4	15	15
Monocytes Within (baseline) - within (Day 8)	4	4	15	16
Neutrophils Within (baseline) - within (Day 8)	3	4	12	15
Platelets Within (baseline) - within (Day 8)	3	3	11	15
WBC Within (baseline) - within (Day 8)	3	2	15	16
ALT Above (baseline) - within (Day 8)	0	0	1	0
AST Above (baseline) - within (Day 8)	1	0	0	0
Creatinine Above (baseline) - within (Day 8)	1	0	0	1
Urea Nitrogen Above (baseline) - within (Day 8)	0	0	0	0
Basophils Above (baseline) - within (Day 8)	0	0	0	0
Eosinophils Above (baseline) - within (Day 8)	0	0	0	0
Hemoglobin Above (baseline) - within (Day 8)	0	0	0	0
Lymphocytes Above (baseline) - within (Day 8)	0	0	0	0
Monocytes Above (baseline) - within (Day 8)	0	0	0	0

Neutrophils Above (baseline) - within (Day 8)	1	0	3	1
Platelets Above (baseline) - within (Day 8)	0	0	0	0
WBC Above (baseline) - within (Day 8)	0	0	1	0
ALT Below (baseline) - above (Day 8)	0	0	0	0
AST Below (baseline) - above (Day 8)	0	0	0	0
Creatinine Below (baseline) - above (Day 8)	0	0	0	0
Urea Nitrogen Below (baseline) - above (Day 8)	0	0	0	0
Basophils Below (baseline) - above (Day 8)	0	0	0	0
Eosinophils Below (baseline) - above (Day 8)	0	0	0	0
Hemoglobin Below (baseline) - above (Day 8)	0	0	0	0
Lymphocytes Below (baseline) - above (Day 8)	0	0	0	0
Monocytes Below (baseline) - above (Day 8)	0	0	0	0
Neutrophils Below (baseline) - above (Day 8)	0	0	0	0
Platelets Below (baseline) - above (Day 8)	0	0	0	0
WBC Below (baseline) - above (Day 8)	0	0	0	0
ALT Within (baseline) - above (Day 8)	0	0	0	0
AST Within (baseline) - above (Day 8)	0	0	0	0
Creatinine Within (baseline) - above (Day 8)	0	1	1	1
Urea Nitrogen Within (baseline) - above (Day 8)	0	0	0	0
Basophils Within (baseline) - above (Day 8)	0	0	0	0
Eosinophils Within (baseline) - above (Day 8)	0	0	1	0
Hemoglobin Within (baseline) - above (Day 8)	0	0	0	0
Lymphocytes Within (baseline) - above (Day 8)	0	0	0	1
Monocytes Within (baseline) - above (Day 8)	0	0	1	0
Neutrophils Within (baseline) - above (Day 8)	0	0	1	0
Platelets Within (baseline) - above (Day 8)	0	0	5	1
WBC Within (baseline) - above (Day 8)	0	0	0	0
ALT Above (baseline) - above (Day 8)	0	0	2	0
AST Above (baseline) - above (Day 8)	0	0	2	0
Creatinine Above (baseline) - above (Day 8)	1	0	1	1
Urea Nitrogen Above (baseline) - above (Day 8)	0	0	0	0
Basophils Above (baseline) - above (Day 8)	0	0	0	0
Eosinophils Above (baseline) - above (Day 8)	0	0	0	0
Hemoglobin Above (baseline) - above (Day 8)	0	0	0	0

Lymphocytes Above (baseline) - above (Day 8)	0	0	1	0
Monocytes Above (baseline) - above (Day 8)	0	0	0	0
Neutrophils Above (baseline) - above (Day 8)	0	0	0	0
Platelets Above (baseline) - above (Day 8)	1	0	0	0
WBC Above (baseline) - above (Day 8)	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
ALT Below (baseline) - below (Day 8)	0			
AST Below (baseline) - below (Day 8)	0			
Creatinine Below (baseline) - below (Day 8)	0			
Urea Nitrogen Below (baseline) - below (Day 8)	0			
Basophils Below (baseline) - below (Day 8)	0			
Eosinophils Below (baseline) - below (Day 8)	0			
Hemoglobin Below (baseline) - below (Day 8)	0			
Lymphocytes Below (baseline) - below (Day 8)	0			
Monocytes Below (baseline) - below (Day 8)	0			
Neutrophils Below (baseline) - below (Day 8)	0			
Platelets Below (baseline) - below (Day 8)	0			
WBC Below (baseline) - below (Day 8)	0			
ALT Within (baseline) - below (Day 8)	0			
AST Within (baseline) - below (Day 8)	0			
Creatinine Within (baseline) - below (Day 8)	0			
Urea Nitrogen Within (baseline) - below (Day 8)	0			
Basophils Within (baseline) - below (Day 8)	0			
Eosinophils Within (baseline) - below (Day 8)	0			
Hemoglobin Within (baseline) - below (Day 8)	0			
Lymphocytes Within (baseline) - below (Day 8)	0			
Monocytes Within (baseline) - below (Day 8)	0			
Neutrophils Within (baseline) - below (Day 8)	0			
Platelets Within (baseline) - below (Day 8)	0			
WBC Within (baseline) - below (Day 8)	1			

ALT Above (baseline) - below (Day 8)	0			
AST Above (baseline) - below (Day 8)	0			
Creatinine Above (baseline) - below (Day 8)	0			
Urea Nitrogen Above (baseline) - below (Day 8)	0			
Basophils Above (baseline) - below (Day 8)	0			
Eosinophils Above (baseline) - below (Day 8)	0			
Hemoglobin Above (baseline) - below (Day 8)	0			
Lymphocytes Above (baseline) - below (Day 8)	0			
Monocytes Above (baseline) - below (Day 8)	0			
Neutrophils Above (baseline) - below (Day 8)	0			
Platelets Above (baseline) - below (Day 8)	0			
WBC Above (baseline) - below (Day 8)	0			
ALT Below (baseline) - within (Day 8)	0			
AST Below (baseline) - within (Day 8)	0			
Creatinine Below (baseline) - within (Day 8)	0			
Urea Nitrogen Below (baseline) - within (Day 8)	0			
Basophils Below (baseline) - within (Day 8)	0			
Eosinophils Below (baseline) - within (Day 8)	0			
Hemoglobin Below (baseline) - within (Day 8)	0			
Lymphocytes Below (baseline) - within (Day 8)	0			
Monocytes Below (baseline) - within (Day 8)	0			
Neutrophils Below (baseline) - within (Day 8)	0			
Platelets Below (baseline) - within (Day 8)	0			
WBC Below (baseline) - within (Day 8)	0			
ALT Within (baseline) - within (Day 8)	10			
AST Within (baseline) - within (Day 8)	9			
Creatinine Within (baseline) - within (Day 8)	8			
Urea Nitrogen Within (baseline) - within (Day 8)	10			
Basophils Within (baseline) - within (Day 8)	10			
Eosinophils Within (baseline) - within (Day 8)	10			
Hemoglobin Within (baseline) - within (Day 8)	9			
Lymphocytes Within (baseline) - within (Day 8)	10			
Monocytes Within (baseline) - within (Day 8)	10			
Neutrophils Within (baseline) - within (Day 8)	9			

Platelets Within (baseline) - within (Day 8)	10			
WBC Within (baseline) - within (Day 8)	9			
ALT Above (baseline) - within (Day 8)	0			
AST Above (baseline) - within (Day 8)	1			
Creatinine Above (baseline) - within (Day 8)	0			
Urea Nitrogen Above (baseline) - within (Day 8)	0			
Basophils Above (baseline) - within (Day 8)	0			
Eosinophils Above (baseline) - within (Day 8)	0			
Hemoglobin Above (baseline) - within (Day 8)	0			
Lymphocytes Above (baseline) - within (Day 8)	0			
Monocytes Above (baseline) - within (Day 8)	0			
Neutrophils Above (baseline) - within (Day 8)	0			
Platelets Above (baseline) - within (Day 8)	0			
WBC Above (baseline) - within (Day 8)	0			
ALT Below (baseline) - above (Day 8)	0			
AST Below (baseline) - above (Day 8)	0			
Creatinine Below (baseline) - above (Day 8)	0			
Urea Nitrogen Below (baseline) - above (Day 8)	0			
Basophils Below (baseline) - above (Day 8)	0			
Eosinophils Below (baseline) - above (Day 8)	0			
Hemoglobin Below (baseline) - above (Day 8)	0			
Lymphocytes Below (baseline) - above (Day 8)	0			
Monocytes Below (baseline) - above (Day 8)	0			
Neutrophils Below (baseline) - above (Day 8)	0			
Platelets Below (baseline) - above (Day 8)	0			
WBC Below (baseline) - above (Day 8)	0			
ALT Within (baseline) - above (Day 8)	0			
AST Within (baseline) - above (Day 8)	0			
Creatinine Within (baseline) - above (Day 8)	2			
Urea Nitrogen Within (baseline) - above (Day 8)	0			
Basophils Within (baseline) - above (Day 8)	0			
Eosinophils Within (baseline) - above (Day 8)	0			
Hemoglobin Within (baseline) - above (Day 8)	0			
Lymphocytes Within (baseline) - above (Day 8)	0			

Monocytes Within (baseline) - above (Day 8)	0			
Neutrophils Within (baseline) - above (Day 8)	1			
Platelets Within (baseline) - above (Day 8)	0			
WBC Within (baseline) - above (Day 8)	0			
ALT Above (baseline) - above (Day 8)	0			
AST Above (baseline) - above (Day 8)	0			
Creatinine Above (baseline) - above (Day 8)	0			
Urea Nitrogen Above (baseline) - above (Day 8)	0			
Basophils Above (baseline) - above (Day 8)	0			
Eosinophils Above (baseline) - above (Day 8)	0			
Hemoglobin Above (baseline) - above (Day 8)	1			
Lymphocytes Above (baseline) - above (Day 8)	0			
Monocytes Above (baseline) - above (Day 8)	0			
Neutrophils Above (baseline) - above (Day 8)	0			
Platelets Above (baseline) - above (Day 8)	0			
WBC Above (baseline) - above (Day 8)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 64

End point title	Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 64 ^[27] ^[28]
-----------------	---

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 64 (7 days after the second study intervention administration) compared to Baseline (Day 57)

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all

the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	15	15
Units: Participants				
ALT Below (baseline) - below (Day 64)	0	0	0	0
AST Below (baseline) - below (Day 64)	0	0	0	0
Creatinine Below (baseline) - below (Day 64)	0	0	0	0
Urea Nitrogen Below (baseline) - below (Day 64)	0	0	0	0
Basophils Below (baseline) - below (Day 64)	0	0	0	0
Eosinophils Below (baseline) - below (Day 64)	0	0	0	0
Hemoglobin Below (baseline) - below (Day 64)	0	0	0	0
Lymphocytes Below (baseline) - below (Day 64)	0	0	0	0
Monocytes Below (baseline) - below (Day 64)	0	0	0	0
Neutrophils Below (baseline) - below (Day 64)	0	0	0	0
Platelets Below (baseline) - below (Day 64)	0	0	0	0
WBC Below (baseline) - below (Day 64)	0	1	0	0
ALT Within (baseline) - below (Day 64)	0	0	0	0
AST Within (baseline) - below (Day 64)	0	0	0	0
Creatinine Within (baseline) - below (Day 64)	0	0	0	0
Urea Nitrogen Within (baseline) - below (Day 64)	0	0	0	0
Basophils Within (baseline) - below (Day 64)	0	0	0	0
Eosinophils Within (baseline) - below (Day 64)	0	0	0	0
Hemoglobin Within (baseline) - below (Day 64)	0	0	0	0
Lymphocytes Within (baseline) - below (Day 64)	0	0	0	0
Monocytes Within (baseline) - below (Day 64)	0	0	0	0
Neutrophils Within (baseline) - below (Day 64)	0	0	0	0
Platelets Within (baseline) - below (Day 64)	0	0	0	0
WBC Within (baseline) - below (Day 64)	1	0	1	0
ALT Above (baseline) - below (Day 64)	0	0	0	0
AST Above (baseline) - below (Day 64)	0	0	0	0
Creatinine Above (baseline) - below (Day 64)	0	0	0	0
Urea Nitrogen Above (baseline) - below (Day 64)	0	0	0	0

Basophils Above (baseline) - below (Day 64)	0	0	0	0
Eosinophils Above (baseline) - below (Day 64)	0	0	0	0
Hemoglobin Above (baseline) - below (Day 64)	0	0	0	0
Lymphocytes Above (baseline) - below (Day 64)	0	0	0	0
Monocytes Above (baseline) - below (Day 64)	0	0	0	0
Neutrophils Above (baseline) - below (Day 64)	0	0	0	0
Platelets Above (baseline) - below (Day 64)	0	0	0	0
WBC Above (baseline) - below (Day 64)	0	0	0	0
ALT Below (baseline) - within (Day 64)	0	0	0	0
AST Below (baseline) - within (Day 64)	0	0	0	0
Creatinine Below (baseline) - within (Day 64)	0	0	0	0
Urea Nitrogen Below (baseline) - within (Day 64)	1	0	0	0
Basophils Below (baseline) - within (Day 64)	0	0	0	0
Eosinophils Below (baseline) - within (Day 64)	0	0	0	0
Hemoglobin Below (baseline) - within (Day 64)	0	0	0	0
Lymphocytes Below (baseline) - within (Day 64)	0	0	0	0
Monocytes Below (baseline) - within (Day 64)	0	0	0	0
Neutrophils Below (baseline) - within (Day 64)	0	0	0	0
Platelets Below (baseline) - within (Day 64)	0	1	0	0
WBC Below (baseline) - within (Day 64)	0	0	0	0
ALT Within (baseline) - within (Day 64)	4	4	12	14
AST Within (baseline) - within (Day 64)	2	4	13	14
Creatinine Within (baseline) - within (Day 64)	3	4	14	13
Urea Nitrogen Within (baseline) - within (Day 64)	3	4	15	14
Basophils Within (baseline) - within (Day 64)	4	4	15	15
Eosinophils Within (baseline) - within (Day 64)	4	4	15	15
Hemoglobin Within (baseline) - within (Day 64)	4	4	15	15
Lymphocytes Within (baseline) - within (Day 64)	4	4	15	15
Monocytes Within (baseline) - within (Day 64)	4	4	15	15
Neutrophils Within (baseline) - within (Day 64)	3	4	11	14
Platelets Within (baseline) - within (Day 64)	3	3	13	13
WBC Within (baseline) - within (Day 64)	3	3	14	15
ALT Above (baseline) - within (Day 64)	0	0	2	0
AST Above (baseline) - within (Day 64)	1	0	1	1

Creatinine Above (baseline) - within (Day 64)	0	0	0	1
Urea Nitrogen Above (baseline) - within (Day 64)	0	0	0	0
Basophils Above (baseline) - within (Day 64)	0	0	0	0
Eosinophils Above (baseline) - within (Day 64)	0	0	0	0
Hemoglobin Above (baseline) - within (Day 64)	0	0	0	0
Lymphocytes Above (baseline) - within (Day 64)	0	0	0	0
Monocytes Above (baseline) - within (Day 64)	0	0	0	0
Neutrophils Above (baseline) - within (Day 64)	0	0	1	1
Platelets Above (baseline) - within (Day 64)	0	0	0	0
WBC Above (baseline) - within (Day 64)	0	0	0	0
ALT Below (baseline) - above (Day 64)	0	0	0	0
AST Below (baseline) - above (Day 64)	0	0	0	0
Creatinine Below (baseline) - above (Day 64)	0	0	0	0
Urea Nitrogen Below (baseline) - above (Day 64)	0	0	0	0
Basophils Below (baseline) - above (Day 64)	0	0	0	0
Eosinophils Below (baseline) - above (Day 64)	0	0	0	0
Hemoglobin Below (baseline) - above (Day 64)	0	0	0	0
Lymphocytes Below (baseline) - above (Day 64)	0	0	0	0
Monocytes Below (baseline) - above (Day 64)	0	0	0	0
Neutrophils Below (baseline) - above (Day 64)	0	0	0	0
Platelets Below (baseline) - above (Day 64)	0	0	0	0
WBC Below (baseline) - above (Day 64)	0	0	0	0
ALT Within (baseline) - above (Day 64)	0	0	0	1
AST Within (baseline) - above (Day 64)	1	0	0	0
Creatinine Within (baseline) - above (Day 64)	0	0	0	0
Urea Nitrogen Within (baseline) - above (Day 64)	0	0	0	1
Basophils Within (baseline) - above (Day 64)	0	0	0	0
Eosinophils Within (baseline) - above (Day 64)	0	0	0	0
Hemoglobin Within (baseline) - above (Day 64)	0	0	0	0
Lymphocytes Within (baseline) - above (Day 64)	0	0	0	0
Monocytes Within (baseline) - above (Day 64)	0	0	0	0
Neutrophils Within (baseline) - above (Day 64)	1	0	2	0
Platelets Within (baseline) - above (Day 64)	0	0	1	2
WBC Within (baseline) - above (Day 64)	0	0	0	0

ALT Above (baseline) - above (Day 64)	0	0	1	0
AST Above (baseline) - above (Day 64)	0	0	1	0
Creatinine Above (baseline) - above (Day 64)	1	0	1	1
Urea Nitrogen Above (baseline) - above (Day 64)	0	0	0	0
Basophils Above (baseline) - above (Day 64)	0	0	0	0
Eosinophils Above (baseline) - above (Day 64)	0	0	0	0
Hemoglobin Above (baseline) - above (Day 64)	0	0	0	0
Lymphocytes Above (baseline) - above (Day 64)	0	0	0	0
Monocytes Above (baseline) - above (Day 64)	0	0	0	0
Neutrophils Above (baseline) - above (Day 64)	0	0	1	0
Platelets Above (baseline) - above (Day 64)	1	0	1	0
WBC Above (baseline) - above (Day 64)	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
ALT Below (baseline) - below (Day 64)	0			
AST Below (baseline) - below (Day 64)	0			
Creatinine Below (baseline) - below (Day 64)	0			
Urea Nitrogen Below (baseline) - below (Day 64)	0			
Basophils Below (baseline) - below (Day 64)	0			
Eosinophils Below (baseline) - below (Day 64)	0			
Hemoglobin Below (baseline) - below (Day 64)	0			
Lymphocytes Below (baseline) - below (Day 64)	0			
Monocytes Below (baseline) - below (Day 64)	0			
Neutrophils Below (baseline) - below (Day 64)	0			
Platelets Below (baseline) - below (Day 64)	0			
WBC Below (baseline) - below (Day 64)	0			
ALT Within (baseline) - below (Day 64)	0			
AST Within (baseline) - below (Day 64)	0			
Creatinine Within (baseline) - below (Day 64)	0			
Urea Nitrogen Within (baseline) - below (Day 64)	0			
Basophils Within (baseline) - below (Day 64)	0			

Eosinophils Within (baseline) - below (Day 64)	0			
Hemoglobin Within (baseline) - below (Day 64)	0			
Lymphocytes Within (baseline) - below (Day 64)	0			
Monocytes Within (baseline) - below (Day 64)	0			
Neutrophils Within (baseline) - below (Day 64)	0			
Platelets Within (baseline) - below (Day 64)	0			
WBC Within (baseline) - below (Day 64)	0			
ALT Above (baseline) - below (Day 64)	0			
AST Above (baseline) - below (Day 64)	0			
Creatinine Above (baseline) - below (Day 64)	0			
Urea Nitrogen Above (baseline) - below (Day 64)	0			
Basophils Above (baseline) - below (Day 64)	0			
Eosinophils Above (baseline) - below (Day 64)	0			
Hemoglobin Above (baseline) - below (Day 64)	0			
Lymphocytes Above (baseline) - below (Day 64)	0			
Monocytes Above (baseline) - below (Day 64)	0			
Neutrophils Above (baseline) - below (Day 64)	0			
Platelets Above (baseline) - below (Day 64)	0			
WBC Above (baseline) - below (Day 64)	0			
ALT Below (baseline) - within (Day 64)	0			
AST Below (baseline) - within (Day 64)	0			
Creatinine Below (baseline) - within (Day 64)	0			
Urea Nitrogen Below (baseline) - within (Day 64)	0			
Basophils Below (baseline) - within (Day 64)	0			
Eosinophils Below (baseline) - within (Day 64)	0			
Hemoglobin Below (baseline) - within (Day 64)	1			
Lymphocytes Below (baseline) - within (Day 64)	0			
Monocytes Below (baseline) - within (Day 64)	0			
Neutrophils Below (baseline) - within (Day 64)	0			
Platelets Below (baseline) - within (Day 64)	0			
WBC Below (baseline) - within (Day 64)	0			
ALT Within (baseline) - within (Day 64)	10			
AST Within (baseline) - within (Day 64)	10			
Creatinine Within (baseline) - within (Day 64)	7			

Urea Nitrogen Within (baseline) - within (Day 64)	10			
Basophils Within (baseline) - within (Day 64)	10			
Eosinophils Within (baseline) - within (Day 64)	10			
Hemoglobin Within (baseline) - within (Day 64)	9			
Lymphocytes Within (baseline) - within (Day 64)	9			
Monocytes Within (baseline) - within (Day 64)	10			
Neutrophils Within (baseline) - within (Day 64)	6			
Platelets Within (baseline) - within (Day 64)	10			
WBC Within (baseline) - within (Day 64)	7			
ALT Above (baseline) - within (Day 64)	0			
AST Above (baseline) - within (Day 64)	0			
Creatinine Above (baseline) - within (Day 64)	2			
Urea Nitrogen Above (baseline) - within (Day 64)	0			
Basophils Above (baseline) - within (Day 64)	0			
Eosinophils Above (baseline) - within (Day 64)	0			
Hemoglobin Above (baseline) - within (Day 64)	0			
Lymphocytes Above (baseline) - within (Day 64)	0			
Monocytes Above (baseline) - within (Day 64)	0			
Neutrophils Above (baseline) - within (Day 64)	2			
Platelets Above (baseline) - within (Day 64)	0			
WBC Above (baseline) - within (Day 64)	2			
ALT Below (baseline) - above (Day 64)	0			
AST Below (baseline) - above (Day 64)	0			
Creatinine Below (baseline) - above (Day 64)	0			
Urea Nitrogen Below (baseline) - above (Day 64)	0			
Basophils Below (baseline) - above (Day 64)	0			
Eosinophils Below (baseline) - above (Day 64)	0			
Hemoglobin Below (baseline) - above (Day 64)	0			
Lymphocytes Below (baseline) - above (Day 64)	0			
Monocytes Below (baseline) - above (Day 64)	0			
Neutrophils Below (baseline) - above (Day 64)	0			
Platelets Below (baseline) - above (Day 64)	0			
WBC Below (baseline) - above (Day 64)	0			
ALT Within (baseline) - above (Day 64)	0			

AST Within (baseline) - above (Day 64)	0			
Creatinine Within (baseline) - above (Day 64)	1			
Urea Nitrogen Within (baseline) - above (Day 64)	0			
Basophils Within (baseline) - above (Day 64)	0			
Eosinophils Within (baseline) - above (Day 64)	0			
Hemoglobin Within (baseline) - above (Day 64)	0			
Lymphocytes Within (baseline) - above (Day 64)	1			
Monocytes Within (baseline) - above (Day 64)	0			
Neutrophils Within (baseline) - above (Day 64)	0			
Platelets Within (baseline) - above (Day 64)	0			
WBC Within (baseline) - above (Day 64)	0			
ALT Above (baseline) - above (Day 64)	0			
AST Above (baseline) - above (Day 64)	0			
Creatinine Above (baseline) - above (Day 64)	0			
Urea Nitrogen Above (baseline) - above (Day 64)	0			
Basophils Above (baseline) - above (Day 64)	0			
Eosinophils Above (baseline) - above (Day 64)	0			
Hemoglobin Above (baseline) - above (Day 64)	0			
Lymphocytes Above (baseline) - above (Day 64)	0			
Monocytes Above (baseline) - above (Day 64)	0			
Neutrophils Above (baseline) - above (Day 64)	2			
Platelets Above (baseline) - above (Day 64)	0			
WBC Above (baseline) - above (Day 64)	1			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 176

End point title	Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 176 ^[29] ^[30]
-----------------	--

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified

visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 176 (7 days after the third study intervention administration) compared to Baseline (Day 169)

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	13	14
Units: Participants				
ALT Below (baseline) - below (Day 176)	0	0	0	0
AST Below (baseline) - below (Day 176)	0	0	0	0
Creatinine Below (baseline) - below (Day 176)	0	0	0	0
Urea Nitrogen Below (baseline) - below (Day 176)	1	0	0	0
Basophils Below (baseline) - below (Day 176)	0	0	0	0
Eosinophils Below (baseline) - below (Day 176)	0	0	0	0
Hemoglobin Below (baseline) - below (Day 176)	0	0	0	0
Lymphocytes Below (baseline) - below (Day 176)	0	0	0	0
Monocytes Below (baseline) - below (Day 176)	0	0	0	0
Neutrophils Below (baseline) - below (Day 176)	0	0	0	0
Platelets Below (baseline) - below (Day 176)	0	0	0	0
WBC Below (baseline) - below (Day 176)	0	0	0	0
ALT Within (baseline) - below (Day 176)	0	0	0	0
AST Within (baseline) - below (Day 176)	0	0	0	0
Creatinine Within (baseline) - below (Day 176)	0	0	0	0
Urea Nitrogen Within (baseline) - below (Day 176)	0	0	0	0
Basophils Within (baseline) - below (Day 176)	0	0	0	0
Eosinophils Within (baseline) - below (Day 176)	0	0	0	0
Hemoglobin Within (baseline) - below (Day 176)	0	0	0	0
Lymphocytes Within (baseline) - below (Day 176)	0	0	0	0

Monocytes Within (baseline) - below (Day 176)	0	0	0	0
Neutrophils Within (baseline) - below (Day 176)	0	0	0	0
Platelets Within (baseline) - below (Day 176)	0	0	0	0
WBC Within (baseline) - below (Day 176)	0	0	0	0
ALT Above (baseline) - below (Day 176)	0	0	0	0
AST Above (baseline) - below (Day 176)	0	0	0	0
Creatinine Above (baseline) - below (Day 176)	0	0	0	0
Urea Nitrogen Above (baseline) - below (Day 176)	0	0	0	0
Basophils Above (baseline) - below (Day 176)	0	0	0	0
Eosinophils Above (baseline) - below (Day 176)	0	0	0	0
Hemoglobin Above (baseline) - below (Day 176)	0	0	0	0
Lymphocytes Above (baseline) - below (Day 176)	0	0	0	0
Monocytes Above (baseline) - below (Day 176)	0	0	0	0
Neutrophils Above (baseline) - below (Day 176)	0	0	0	0
Platelets Above (baseline) - below (Day 176)	0	0	0	0
WBC Above (baseline) - below (Day 176)	0	0	0	0
ALT Below (baseline) - within (Day 176)	0	0	0	0
AST Below (baseline) - within (Day 176)	0	0	0	0
Creatinine Below (baseline) - within (Day 176)	0	0	0	0
Urea Nitrogen Below (baseline) - within (Day 176)	0	0	0	0
Basophils Below (baseline) - within (Day 176)	0	0	0	0
Eosinophils Below (baseline) - within (Day 176)	0	0	0	0
Hemoglobin Below (baseline) - within (Day 176)	0	0	0	1
Lymphocytes Below (baseline) - within (Day 176)	0	0	0	0
Monocytes Below (baseline) - within (Day 176)	0	0	0	0
Neutrophils Below (baseline) - within (Day 176)	0	0	0	0
Platelets Below (baseline) - within (Day 176)	0	0	0	1
WBC Below (baseline) - within (Day 176)	0	0	0	0
ALT Within (baseline) - within (Day 176)	4	3	11	13
AST Within (baseline) - within (Day 176)	4	3	12	14
Creatinine Within (baseline) - within (Day 176)	3	3	10	10
Urea Nitrogen Within (baseline) - within (Day 176)	3	3	13	13
Basophils Within (baseline) - within (Day 176)	4	3	13	14

Eosinophils Within (baseline) - within (Day 176)	4	3	12	14
Hemoglobin Within (baseline) - within (Day 176)	4	3	13	13
Lymphocytes Within (baseline) - within (Day 176)	4	3	13	14
Monocytes Within (baseline) - within (Day 176)	4	3	13	14
Neutrophils Within (baseline) - within (Day 176)	1	3	8	11
Platelets Within (baseline) - within (Day 176)	2	3	9	12
WBC Within (baseline) - within (Day 176)	4	3	13	12
ALT Above (baseline) - within (Day 176)	0	0	1	0
AST Above (baseline) - within (Day 176)	0	0	1	0
Creatinine Above (baseline) - within (Day 176)	0	0	0	0
Urea Nitrogen Above (baseline) - within (Day 176)	0	0	0	0
Basophils Above (baseline) - within (Day 176)	0	0	0	0
Eosinophils Above (baseline) - within (Day 176)	0	0	0	0
Hemoglobin Above (baseline) - within (Day 176)	0	0	0	0
Lymphocytes Above (baseline) - within (Day 176)	0	0	0	0
Monocytes Above (baseline) - within (Day 176)	0	0	0	0
Neutrophils Above (baseline) - within (Day 176)	1	0	2	1
Platelets Above (baseline) - within (Day 176)	0	0	1	0
WBC Above (baseline) - within (Day 176)	0	0	0	1
ALT Below (baseline) - above (Day 176)	0	0	0	0
AST Below (baseline) - above (Day 176)	0	0	0	0
Creatinine Below (baseline) - above (Day 176)	0	0	0	0
Urea Nitrogen Below (baseline) - above (Day 176)	0	0	0	0
Basophils Below (baseline) - above (Day 176)	0	0	0	0
Eosinophils Below (baseline) - above (Day 176)	0	0	0	0
Hemoglobin Below (baseline) - above (Day 176)	0	0	0	0
Lymphocytes Below (baseline) - above (Day 176)	0	0	0	0
Monocytes Below (baseline) - above (Day 176)	0	0	0	0
Neutrophils Below (baseline) - above (Day 176)	0	0	0	0
Platelets Below (baseline) - above (Day 176)	0	0	0	0
WBC Below (baseline) - above (Day 176)	0	0	0	0
ALT Within (baseline) - above (Day 176)	0	0	1	1

AST Within (baseline) - above (Day 176)	0	0	0	0
Creatinine Within (baseline) - above (Day 176)	0	0	2	3
Urea Nitrogen Within (baseline) - above (Day 176)	0	0	0	0
Basophils Within (baseline) - above (Day 176)	0	0	0	0
Eosinophils Within (baseline) - above (Day 176)	0	0	1	0
Hemoglobin Within (baseline) - above (Day 176)	0	0	0	0
Lymphocytes Within (baseline) - above (Day 176)	0	0	0	0
Monocytes Within (baseline) - above (Day 176)	0	0	0	0
Neutrophils Within (baseline) - above (Day 176)	2	0	2	1
Platelets Within (baseline) - above (Day 176)	2	0	2	1
WBC Within (baseline) - above (Day 176)	0	0	0	1
ALT Above (baseline) - above (Day 176)	0	0	0	0
AST Above (baseline) - above (Day 176)	0	0	0	0
Creatinine Above (baseline) - above (Day 176)	1	0	1	1
Urea Nitrogen Above (baseline) - above (Day 176)	0	0	0	1
Basophils Above (baseline) - above (Day 176)	0	0	0	0
Eosinophils Above (baseline) - above (Day 176)	0	0	0	0
Hemoglobin Above (baseline) - above (Day 176)	0	0	0	0
Lymphocytes Above (baseline) - above (Day 176)	0	0	0	0
Monocytes Above (baseline) - above (Day 176)	0	0	0	0
Neutrophils Above (baseline) - above (Day 176)	0	0	1	1
Platelets Above (baseline) - above (Day 176)	0	0	1	0
WBC Above (baseline) - above (Day 176)	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
ALT Below (baseline) - below (Day 176)	0			
AST Below (baseline) - below (Day 176)	0			
Creatinine Below (baseline) - below (Day 176)	0			
Urea Nitrogen Below (baseline) - below (Day 176)	0			

Basophils Below (baseline) - below (Day 176)	0			
Eosinophils Below (baseline) - below (Day 176)	0			
Hemoglobin Below (baseline) - below (Day 176)	0			
Lymphocytes Below (baseline) - below (Day 176)	0			
Monocytes Below (baseline) - below (Day 176)	0			
Neutrophils Below (baseline) - below (Day 176)	0			
Platelets Below (baseline) - below (Day 176)	0			
WBC Below (baseline) - below (Day 176)	0			
ALT Within (baseline) - below (Day 176)	0			
AST Within (baseline) - below (Day 176)	0			
Creatinine Within (baseline) - below (Day 176)	0			
Urea Nitrogen Within (baseline) - below (Day 176)	0			
Basophils Within (baseline) - below (Day 176)	0			
Eosinophils Within (baseline) - below (Day 176)	0			
Hemoglobin Within (baseline) - below (Day 176)	0			
Lymphocytes Within (baseline) - below (Day 176)	0			
Monocytes Within (baseline) - below (Day 176)	0			
Neutrophils Within (baseline) - below (Day 176)	0			
Platelets Within (baseline) - below (Day 176)	0			
WBC Within (baseline) - below (Day 176)	0			
ALT Above (baseline) - below (Day 176)	0			
AST Above (baseline) - below (Day 176)	0			
Creatinine Above (baseline) - below (Day 176)	0			
Urea Nitrogen Above (baseline) - below (Day 176)	0			
Basophils Above (baseline) - below (Day 176)	0			
Eosinophils Above (baseline) - below (Day 176)	0			
Hemoglobin Above (baseline) - below (Day 176)	0			
Lymphocytes Above (baseline) - below (Day 176)	0			
Monocytes Above (baseline) - below (Day 176)	0			
Neutrophils Above (baseline) - below (Day 176)	0			
Platelets Above (baseline) - below (Day 176)	0			
WBC Above (baseline) - below (Day 176)	0			

ALT Below (baseline) - within (Day 176)	0			
AST Below (baseline) - within (Day 176)	0			
Creatinine Below (baseline) - within (Day 176)	0			
Urea Nitrogen Below (baseline) - within (Day 176)	0			
Basophils Below (baseline) - within (Day 176)	0			
Eosinophils Below (baseline) - within (Day 176)	0			
Hemoglobin Below (baseline) - within (Day 176)	0			
Lymphocytes Below (baseline) - within (Day 176)	0			
Monocytes Below (baseline) - within (Day 176)	0			
Neutrophils Below (baseline) - within (Day 176)	0			
Platelets Below (baseline) - within (Day 176)	0			
WBC Below (baseline) - within (Day 176)	0			
ALT Within (baseline) - within (Day 176)	10			
AST Within (baseline) - within (Day 176)	10			
Creatinine Within (baseline) - within (Day 176)	6			
Urea Nitrogen Within (baseline) - within (Day 176)	10			
Basophils Within (baseline) - within (Day 176)	10			
Eosinophils Within (baseline) - within (Day 176)	10			
Hemoglobin Within (baseline) - within (Day 176)	9			
Lymphocytes Within (baseline) - within (Day 176)	10			
Monocytes Within (baseline) - within (Day 176)	10			
Neutrophils Within (baseline) - within (Day 176)	8			
Platelets Within (baseline) - within (Day 176)	10			
WBC Within (baseline) - within (Day 176)	9			
ALT Above (baseline) - within (Day 176)	0			
AST Above (baseline) - within (Day 176)	0			
Creatinine Above (baseline) - within (Day 176)	1			
Urea Nitrogen Above (baseline) - within (Day 176)	0			
Basophils Above (baseline) - within (Day 176)	0			
Eosinophils Above (baseline) - within (Day 176)	0			
Hemoglobin Above (baseline) - within (Day 176)	0			
Lymphocytes Above (baseline) - within (Day 176)	0			

Monocytes Above (baseline) - within (Day 176)	0			
Neutrophils Above (baseline) - within (Day 176)	1			
Platelets Above (baseline) - within (Day 176)	0			
WBC Above (baseline) - within (Day 176)	0			
ALT Below (baseline) - above (Day 176)	0			
AST Below (baseline) - above (Day 176)	0			
Creatinine Below (baseline) - above (Day 176)	0			
Urea Nitrogen Below (baseline) - above (Day 176)	0			
Basophils Below (baseline) - above (Day 176)	0			
Eosinophils Below (baseline) - above (Day 176)	0			
Hemoglobin Below (baseline) - above (Day 176)	0			
Lymphocytes Below (baseline) - above (Day 176)	0			
Monocytes Below (baseline) - above (Day 176)	0			
Neutrophils Below (baseline) - above (Day 176)	0			
Platelets Below (baseline) - above (Day 176)	0			
WBC Below (baseline) - above (Day 176)	0			
ALT Within (baseline) - above (Day 176)	0			
AST Within (baseline) - above (Day 176)	0			
Creatinine Within (baseline) - above (Day 176)	2			
Urea Nitrogen Within (baseline) - above (Day 176)	0			
Basophils Within (baseline) - above (Day 176)	0			
Eosinophils Within (baseline) - above (Day 176)	0			
Hemoglobin Within (baseline) - above (Day 176)	0			
Lymphocytes Within (baseline) - above (Day 176)	0			
Monocytes Within (baseline) - above (Day 176)	0			
Neutrophils Within (baseline) - above (Day 176)	1			
Platelets Within (baseline) - above (Day 176)	0			
WBC Within (baseline) - above (Day 176)	1			
ALT Above (baseline) - above (Day 176)	0			
AST Above (baseline) - above (Day 176)	0			
Creatinine Above (baseline) - above (Day 176)	1			
Urea Nitrogen Above (baseline) - above (Day 176)	0			

Basophils Above (baseline) - above (Day 176)	0			
Eosinophils Above (baseline) - above (Day 176)	0			
Hemoglobin Above (baseline) - above (Day 176)	1			
Lymphocytes Above (baseline) - above (Day 176)	0			
Monocytes Above (baseline) - above (Day 176)	0			
Neutrophils Above (baseline) - above (Day 176)	0			
Platelets Above (baseline) - above (Day 176)	0			
WBC Above (baseline) - above (Day 176)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 29

End point title	Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 29 ^[31] ^[32]
-----------------	---

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 29 (28 days after the first study intervention administration) compared to Baseline (Day 1)

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants				
ALT Below (baseline) - below (Day 29)	0	0	0	0
AST Below (baseline) - below (Day 29)	0	0	0	0

Creatinine Below (baseline) - below (Day 29)	0	0	0	0
Urea Nitrogen Below (baseline) - below (Day 29)	0	0	0	0
Basophils Below (baseline) - below (Day 29)	0	0	0	0
Eosinophils Below (baseline) - below (Day 29)	0	0	0	0
Hemoglobin Below (baseline) - below (Day 29)	0	0	0	0
Lymphocytes Below (baseline) - below (Day 29)	0	0	0	0
Monocytes Below (baseline) - below (Day 29)	0	0	0	0
Neutrophils Below (baseline) - below (Day 29)	0	0	0	0
Platelets Below (baseline) - below (Day 29)	0	0	0	0
WBC Below (baseline) - below (Day 29)	0	1	0	0
ALT Within (baseline) - below (Day 29)	0	0	0	0
AST Within (baseline) - below (Day 29)	0	0	0	0
Creatinine Within (baseline) - below (Day 29)	0	0	0	0
Urea Nitrogen Within (baseline) - below (Day 29)	0	0	0	0
Basophils Within (baseline) - below (Day 29)	0	0	0	0
Eosinophils Within (baseline) - below (Day 29)	0	0	0	0
Hemoglobin Within (baseline) - below (Day 29)	0	0	0	0
Lymphocytes Within (baseline) - below (Day 29)	0	0	0	0
Monocytes Within (baseline) - below (Day 29)	0	0	0	0
Neutrophils Within (baseline) - below (Day 29)	0	0	0	0
Platelets Within (baseline) - below (Day 29)	0	0	0	0
WBC Within (baseline) - below (Day 29)	0	0	0	0
ALT Above (baseline) - below (Day 29)	0	0	0	0
AST Above (baseline) - below (Day 29)	0	0	0	0
Creatinine Above (baseline) - below (Day 29)	0	0	0	0
Urea Nitrogen Above (baseline) - below (Day 29)	0	0	0	0
Basophils Above (baseline) - below (Day 29)	0	0	0	0
Eosinophils Above (baseline) - below (Day 29)	0	0	0	0
Hemoglobin Above (baseline) - below (Day 29)	0	0	0	0
Lymphocytes Above (baseline) - below (Day 29)	0	0	0	0
Monocytes Above (baseline) - below (Day 29)	0	0	0	0
Neutrophils Above (baseline) - below (Day 29)	0	0	0	0
Platelets Above (baseline) - below (Day 29)	0	0	0	0
WBC Above (baseline) - below (Day 29)	0	0	0	0

ALT Below (baseline) - within (Day 29)	0	0	0	0
AST Below (baseline) - within (Day 29)	0	0	0	0
Creatinine Below (baseline) - within (Day 29)	0	0	0	0
Urea Nitrogen Below (baseline) - within (Day 29)	0	0	1	1
Basophils Below (baseline) - within (Day 29)	0	0	0	0
Eosinophils Below (baseline) - within (Day 29)	0	0	0	0
Hemoglobin Below (baseline) - within (Day 29)	0	0	0	0
Lymphocytes Below (baseline) - within (Day 29)	0	0	0	0
Monocytes Below (baseline) - within (Day 29)	0	0	0	0
Neutrophils Below (baseline) - within (Day 29)	0	0	0	0
Platelets Below (baseline) - within (Day 29)	0	1	0	0
WBC Below (baseline) - within (Day 29)	1	1	0	0
ALT Within (baseline) - within (Day 29)	4	4	13	16
AST Within (baseline) - within (Day 29)	3	4	14	16
Creatinine Within (baseline) - within (Day 29)	2	4	15	14
Urea Nitrogen Within (baseline) - within (Day 29)	4	4	15	15
Basophils Within (baseline) - within (Day 29)	4	4	16	16
Eosinophils Within (baseline) - within (Day 29)	4	4	15	16
Hemoglobin Within (baseline) - within (Day 29)	4	4	16	15
Lymphocytes Within (baseline) - within (Day 29)	4	4	15	16
Monocytes Within (baseline) - within (Day 29)	4	4	16	15
Neutrophils Within (baseline) - within (Day 29)	3	4	12	14
Platelets Within (baseline) - within (Day 29)	2	3	14	16
WBC Within (baseline) - within (Day 29)	3	2	14	15
ALT Above (baseline) - within (Day 29)	0	0	1	0
AST Above (baseline) - within (Day 29)	1	0	2	0
Creatinine Above (baseline) - within (Day 29)	1	0	0	2
Urea Nitrogen Above (baseline) - within (Day 29)	0	0	0	0
Basophils Above (baseline) - within (Day 29)	0	0	0	0
Eosinophils Above (baseline) - within (Day 29)	0	0	0	0
Hemoglobin Above (baseline) - within (Day 29)	0	0	0	0
Lymphocytes Above (baseline) - within (Day 29)	0	0	0	0
Monocytes Above (baseline) - within (Day 29)	0	0	0	0
Neutrophils Above (baseline) - within (Day 29)	0	0	1	1

Platelets Above (baseline) - within (Day 29)	0	0	0	0
WBC Above (baseline) - within (Day 29)	0	0	1	0
ALT Below (baseline) - above (Day 29)	0	0	0	0
AST Below (baseline) - above (Day 29)	0	0	0	0
Creatinine Below (baseline) - above (Day 29)	0	0	0	0
Urea Nitrogen Below (baseline) - above (Day 29)	0	0	0	0
Basophils Below (baseline) - above (Day 29)	0	0	0	0
Eosinophils Below (baseline) - above (Day 29)	0	0	0	0
Hemoglobin Below (baseline) - above (Day 29)	0	0	0	0
Lymphocytes Below (baseline) - above (Day 29)	0	0	0	0
Monocytes Below (baseline) - above (Day 29)	0	0	0	0
Neutrophils Below (baseline) - above (Day 29)	0	0	0	0
Platelets Below (baseline) - above (Day 29)	0	0	0	0
WBC Below (baseline) - above (Day 29)	0	0	0	0
ALT Within (baseline) - above (Day 29)	0	0	0	0
AST Within (baseline) - above (Day 29)	0	0	0	0
Creatinine Within (baseline) - above (Day 29)	0	0	0	0
Urea Nitrogen Within (baseline) - above (Day 29)	0	0	0	0
Basophils Within (baseline) - above (Day 29)	0	0	0	0
Eosinophils Within (baseline) - above (Day 29)	0	0	1	0
Hemoglobin Within (baseline) - above (Day 29)	0	0	0	1
Lymphocytes Within (baseline) - above (Day 29)	0	0	0	0
Monocytes Within (baseline) - above (Day 29)	0	0	0	1
Neutrophils Within (baseline) - above (Day 29)	0	0	1	1
Platelets Within (baseline) - above (Day 29)	1	0	2	0
WBC Within (baseline) - above (Day 29)	0	0	1	1
ALT Above (baseline) - above (Day 29)	0	0	2	0
AST Above (baseline) - above (Day 29)	0	0	0	0
Creatinine Above (baseline) - above (Day 29)	1	0	1	0
Urea Nitrogen Above (baseline) - above (Day 29)	0	0	0	0
Basophils Above (baseline) - above (Day 29)	0	0	0	0
Eosinophils Above (baseline) - above (Day 29)	0	0	0	0
Hemoglobin Above (baseline) - above (Day 29)	0	0	0	0
Lymphocytes Above (baseline) - above (Day 29)	0	0	1	0

Monocytes Above (baseline) - above (Day 29)	0	0	0	0
Neutrophils Above (baseline) - above (Day 29)	1	0	2	0
Platelets Above (baseline) - above (Day 29)	1	0	0	0
WBC Above (baseline) - above (Day 29)	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
ALT Below (baseline) - below (Day 29)	0			
AST Below (baseline) - below (Day 29)	0			
Creatinine Below (baseline) - below (Day 29)	0			
Urea Nitrogen Below (baseline) - below (Day 29)	0			
Basophils Below (baseline) - below (Day 29)	0			
Eosinophils Below (baseline) - below (Day 29)	0			
Hemoglobin Below (baseline) - below (Day 29)	0			
Lymphocytes Below (baseline) - below (Day 29)	0			
Monocytes Below (baseline) - below (Day 29)	0			
Neutrophils Below (baseline) - below (Day 29)	0			
Platelets Below (baseline) - below (Day 29)	0			
WBC Below (baseline) - below (Day 29)	0			
ALT Within (baseline) - below (Day 29)	0			
AST Within (baseline) - below (Day 29)	0			
Creatinine Within (baseline) - below (Day 29)	0			
Urea Nitrogen Within (baseline) - below (Day 29)	0			
Basophils Within (baseline) - below (Day 29)	0			
Eosinophils Within (baseline) - below (Day 29)	0			
Hemoglobin Within (baseline) - below (Day 29)	0			
Lymphocytes Within (baseline) - below (Day 29)	0			
Monocytes Within (baseline) - below (Day 29)	0			
Neutrophils Within (baseline) - below (Day 29)	0			
Platelets Within (baseline) - below (Day 29)	0			
WBC Within (baseline) - below (Day 29)	0			
ALT Above (baseline) - below (Day 29)	0			

AST Above (baseline) - below (Day 29)	0			
Creatinine Above (baseline) - below (Day 29)	0			
Urea Nitrogen Above (baseline) - below (Day 29)	0			
Basophils Above (baseline) - below (Day 29)	0			
Eosinophils Above (baseline) - below (Day 29)	0			
Hemoglobin Above (baseline) - below (Day 29)	0			
Lymphocytes Above (baseline) - below (Day 29)	0			
Monocytes Above (baseline) - below (Day 29)	0			
Neutrophils Above (baseline) - below (Day 29)	0			
Platelets Above (baseline) - below (Day 29)	0			
WBC Above (baseline) - below (Day 29)	0			
ALT Below (baseline) - within (Day 29)	0			
AST Below (baseline) - within (Day 29)	0			
Creatinine Below (baseline) - within (Day 29)	0			
Urea Nitrogen Below (baseline) - within (Day 29)	0			
Basophils Below (baseline) - within (Day 29)	0			
Eosinophils Below (baseline) - within (Day 29)	0			
Hemoglobin Below (baseline) - within (Day 29)	0			
Lymphocytes Below (baseline) - within (Day 29)	0			
Monocytes Below (baseline) - within (Day 29)	0			
Neutrophils Below (baseline) - within (Day 29)	0			
Platelets Below (baseline) - within (Day 29)	0			
WBC Below (baseline) - within (Day 29)	0			
ALT Within (baseline) - within (Day 29)	10			
AST Within (baseline) - within (Day 29)	9			
Creatinine Within (baseline) - within (Day 29)	8			
Urea Nitrogen Within (baseline) - within (Day 29)	10			
Basophils Within (baseline) - within (Day 29)	10			
Eosinophils Within (baseline) - within (Day 29)	10			
Hemoglobin Within (baseline) - within (Day 29)	9			
Lymphocytes Within (baseline) - within (Day 29)	10			
Monocytes Within (baseline) - within (Day 29)	10			
Neutrophils Within (baseline) - within (Day 29)	9			
Platelets Within (baseline) - within (Day 29)	10			

WBC Within (baseline) - within (Day 29)	10			
ALT Above (baseline) - within (Day 29)	0			
AST Above (baseline) - within (Day 29)	1			
Creatinine Above (baseline) - within (Day 29)	0			
Urea Nitrogen Above (baseline) - within (Day 29)	0			
Basophils Above (baseline) - within (Day 29)	0			
Eosinophils Above (baseline) - within (Day 29)	0			
Hemoglobin Above (baseline) - within (Day 29)	0			
Lymphocytes Above (baseline) - within (Day 29)	0			
Monocytes Above (baseline) - within (Day 29)	0			
Neutrophils Above (baseline) - within (Day 29)	0			
Platelets Above (baseline) - within (Day 29)	0			
WBC Above (baseline) - within (Day 29)	0			
ALT Below (baseline) - above (Day 29)	0			
AST Below (baseline) - above (Day 29)	0			
Creatinine Below (baseline) - above (Day 29)	0			
Urea Nitrogen Below (baseline) - above (Day 29)	0			
Basophils Below (baseline) - above (Day 29)	0			
Eosinophils Below (baseline) - above (Day 29)	0			
Hemoglobin Below (baseline) - above (Day 29)	0			
Lymphocytes Below (baseline) - above (Day 29)	0			
Monocytes Below (baseline) - above (Day 29)	0			
Neutrophils Below (baseline) - above (Day 29)	0			
Platelets Below (baseline) - above (Day 29)	0			
WBC Below (baseline) - above (Day 29)	0			
ALT Within (baseline) - above (Day 29)	0			
AST Within (baseline) - above (Day 29)	0			
Creatinine Within (baseline) - above (Day 29)	2			
Urea Nitrogen Within (baseline) - above (Day 29)	0			
Basophils Within (baseline) - above (Day 29)	0			
Eosinophils Within (baseline) - above (Day 29)	0			
Hemoglobin Within (baseline) - above (Day 29)	0			
Lymphocytes Within (baseline) - above (Day 29)	0			
Monocytes Within (baseline) - above (Day 29)	0			

Neutrophils Within (baseline) - above (Day 29)	1			
Platelets Within (baseline) - above (Day 29)	0			
WBC Within (baseline) - above (Day 29)	0			
ALT Above (baseline) - above (Day 29)	0			
AST Above (baseline) - above (Day 29)	0			
Creatinine Above (baseline) - above (Day 29)	0			
Urea Nitrogen Above (baseline) - above (Day 29)	0			
Basophils Above (baseline) - above (Day 29)	0			
Eosinophils Above (baseline) - above (Day 29)	0			
Hemoglobin Above (baseline) - above (Day 29)	1			
Lymphocytes Above (baseline) - above (Day 29)	0			
Monocytes Above (baseline) - above (Day 29)	0			
Neutrophils Above (baseline) - above (Day 29)	0			
Platelets Above (baseline) - above (Day 29)	0			
WBC Above (baseline) - above (Day 29)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 85

End point title	Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 85 ^[33] ^[34]
-----------------	---

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 85 (28 days after the second study intervention administration) compared to Baseline (Day 57)

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	15	15
Units: Participants				
ALT Below (baseline) - below (Day 85)	0	0	0	0
AST Below (baseline) - below (Day 85)	0	0	0	0
Creatinine Below (baseline) - below (Day 85)	0	0	0	0
Urea Nitrogen Below (baseline) - below (Day 85)	0	0	0	0
Basophils Below (baseline) - below (Day 85)	0	0	0	0
Eosinophils Below (baseline) - below (Day 85)	0	0	0	0
Hemoglobin Below (baseline) - below (Day 85)	0	0	0	0
Lymphocytes Below (baseline) - below (Day 85)	0	0	0	0
Monocytes Below (baseline) - below (Day 85)	0	0	0	0
Neutrophils Below (baseline) - below (Day 85)	0	0	0	0
Platelets Below (baseline) - below (Day 85)	0	1	0	0
WBC Below (baseline) - below (Day 85)	0	1	0	0
ALT Within (baseline) - below (Day 85)	0	0	0	0
AST Within (baseline) - below (Day 85)	0	0	0	0
Creatinine Within (baseline) - below (Day 85)	0	0	0	0
Urea Nitrogen Within (baseline) - below (Day 85)	0	0	0	0
Basophils Within (baseline) - below (Day 85)	0	0	0	0
Eosinophils Within (baseline) - below (Day 85)	0	0	0	0
Hemoglobin Within (baseline) - below (Day 85)	0	0	0	1
Lymphocytes Within (baseline) - below (Day 85)	0	0	0	0
Monocytes Within (baseline) - below (Day 85)	0	0	0	0
Neutrophils Within (baseline) - below (Day 85)	0	0	0	0
Platelets Within (baseline) - below (Day 85)	0	0	0	0
WBC Within (baseline) - below (Day 85)	0	1	0	0
ALT Above (baseline) - below (Day 85)	0	0	0	0
AST Above (baseline) - below (Day 85)	0	0	0	0
Creatinine Above (baseline) - below (Day 85)	0	0	0	0
Urea Nitrogen Above (baseline) - below (Day 85)	0	0	0	0
Basophils Above (baseline) - below (Day 85)	0	0	0	0
Eosinophils Above (baseline) - below (Day 85)	0	0	0	0
Hemoglobin Above (baseline) - below (Day 85)	0	0	0	0

Lymphocytes Above (baseline) - below (Day 85)	0	0	0	0
Monocytes Above (baseline) - below (Day 85)	0	0	0	0
Neutrophils Above (baseline) - below (Day 85)	0	0	0	0
Platelets Above (baseline) - below (Day 85)	0	0	0	0
WBC Above (baseline) - below (Day 85)	0	0	0	0
ALT Below (baseline) - within (Day 85)	0	0	0	0
AST Below (baseline) - within (Day 85)	0	0	0	0
Creatinine Below (baseline) - within (Day 85)	0	0	0	0
Urea Nitrogen Below (baseline) - within (Day 85)	1	0	0	0
Basophils Below (baseline) - within (Day 85)	0	0	0	0
Eosinophils Below (baseline) - within (Day 85)	0	0	0	0
Hemoglobin Below (baseline) - within (Day 85)	0	0	0	0
Lymphocytes Below (baseline) - within (Day 85)	0	0	0	0
Monocytes Below (baseline) - within (Day 85)	0	0	0	0
Neutrophils Below (baseline) - within (Day 85)	0	0	0	0
Platelets Below (baseline) - within (Day 85)	0	0	0	0
WBC Below (baseline) - within (Day 85)	0	0	0	0
ALT Within (baseline) - within (Day 85)	4	4	11	15
AST Within (baseline) - within (Day 85)	3	4	13	13
Creatinine Within (baseline) - within (Day 85)	3	4	12	11
Urea Nitrogen Within (baseline) - within (Day 85)	3	4	15	15
Basophils Within (baseline) - within (Day 85)	4	4	15	15
Eosinophils Within (baseline) - within (Day 85)	4	4	15	15
Hemoglobin Within (baseline) - within (Day 85)	4	4	15	14
Lymphocytes Within (baseline) - within (Day 85)	4	4	15	14
Monocytes Within (baseline) - within (Day 85)	4	4	15	15
Neutrophils Within (baseline) - within (Day 85)	4	4	13	14
Platelets Within (baseline) - within (Day 85)	3	3	13	15
WBC Within (baseline) - within (Day 85)	4	2	15	14
ALT Above (baseline) - within (Day 85)	0	0	2	0
AST Above (baseline) - within (Day 85)	1	0	2	1
Creatinine Above (baseline) - within (Day 85)	0	0	0	0
Urea Nitrogen Above (baseline) - within (Day 85)	0	0	0	0
Basophils Above (baseline) - within (Day 85)	0	0	0	0

Eosinophils Above (baseline) - within (Day 85)	0	0	0	0
Hemoglobin Above (baseline) - within (Day 85)	0	0	0	0
Lymphocytes Above (baseline) - within (Day 85)	0	0	0	0
Monocytes Above (baseline) - within (Day 85)	0	0	0	0
Neutrophils Above (baseline) - within (Day 85)	0	0	0	0
Platelets Above (baseline) - within (Day 85)	0	0	1	0
WBC Above (baseline) - within (Day 85)	0	0	0	0
ALT Below (baseline) - above (Day 85)	0	0	0	0
AST Below (baseline) - above (Day 85)	0	0	0	0
Creatinine Below (baseline) - above (Day 85)	0	0	0	0
Urea Nitrogen Below (baseline) - above (Day 85)	0	0	0	0
Basophils Below (baseline) - above (Day 85)	0	0	0	0
Eosinophils Below (baseline) - above (Day 85)	0	0	0	0
Hemoglobin Below (baseline) - above (Day 85)	0	0	0	0
Lymphocytes Below (baseline) - above (Day 85)	0	0	0	0
Monocytes Below (baseline) - above (Day 85)	0	0	0	0
Neutrophils Below (baseline) - above (Day 85)	0	0	0	0
Platelets Below (baseline) - above (Day 85)	0	0	0	0
WBC Below (baseline) - above (Day 85)	0	0	0	0
ALT Within (baseline) - above (Day 85)	0	0	1	0
AST Within (baseline) - above (Day 85)	0	0	0	1
Creatinine Within (baseline) - above (Day 85)	0	0	2	2
Urea Nitrogen Within (baseline) - above (Day 85)	0	0	0	0
Basophils Within (baseline) - above (Day 85)	0	0	0	0
Eosinophils Within (baseline) - above (Day 85)	0	0	0	0
Hemoglobin Within (baseline) - above (Day 85)	0	0	0	0
Lymphocytes Within (baseline) - above (Day 85)	0	0	0	1
Monocytes Within (baseline) - above (Day 85)	0	0	0	0
Neutrophils Within (baseline) - above (Day 85)	0	0	0	0
Platelets Within (baseline) - above (Day 85)	0	0	1	0
WBC Within (baseline) - above (Day 85)	0	0	0	1
ALT Above (baseline) - above (Day 85)	0	0	1	0
AST Above (baseline) - above (Day 85)	0	0	0	0
Creatinine Above (baseline) - above (Day 85)	1	0	1	2

Urea Nitrogen Above (baseline) - above (Day 85)	0	0	0	0
Basophils Above (baseline) - above (Day 85)	0	0	0	0
Eosinophils Above (baseline) - above (Day 85)	0	0	0	0
Hemoglobin Above (baseline) - above (Day 85)	0	0	0	0
Lymphocytes Above (baseline) - above (Day 85)	0	0	0	0
Monocytes Above (baseline) - above (Day 85)	0	0	0	0
Neutrophils Above (baseline) - above (Day 85)	0	0	2	1
Platelets Above (baseline) - above (Day 85)	1	0	0	0
WBC Above (baseline) - above (Day 85)	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
ALT Below (baseline) - below (Day 85)	0			
AST Below (baseline) - below (Day 85)	0			
Creatinine Below (baseline) - below (Day 85)	0			
Urea Nitrogen Below (baseline) - below (Day 85)	0			
Basophils Below (baseline) - below (Day 85)	0			
Eosinophils Below (baseline) - below (Day 85)	0			
Hemoglobin Below (baseline) - below (Day 85)	0			
Lymphocytes Below (baseline) - below (Day 85)	0			
Monocytes Below (baseline) - below (Day 85)	0			
Neutrophils Below (baseline) - below (Day 85)	0			
Platelets Below (baseline) - below (Day 85)	0			
WBC Below (baseline) - below (Day 85)	0			
ALT Within (baseline) - below (Day 85)	0			
AST Within (baseline) - below (Day 85)	0			
Creatinine Within (baseline) - below (Day 85)	0			
Urea Nitrogen Within (baseline) - below (Day 85)	0			
Basophils Within (baseline) - below (Day 85)	0			
Eosinophils Within (baseline) - below (Day 85)	0			
Hemoglobin Within (baseline) - below (Day 85)	0			

Lymphocytes Within (baseline) - below (Day 85)	0			
Monocytes Within (baseline) - below (Day 85)	0			
Neutrophils Within (baseline) - below (Day 85)	0			
Platelets Within (baseline) - below (Day 85)	0			
WBC Within (baseline) - below (Day 85)	0			
ALT Above (baseline) - below (Day 85)	0			
AST Above (baseline) - below (Day 85)	0			
Creatinine Above (baseline) - below (Day 85)	0			
Urea Nitrogen Above (baseline) - below (Day 85)	0			
Basophils Above (baseline) - below (Day 85)	0			
Eosinophils Above (baseline) - below (Day 85)	0			
Hemoglobin Above (baseline) - below (Day 85)	0			
Lymphocytes Above (baseline) - below (Day 85)	0			
Monocytes Above (baseline) - below (Day 85)	0			
Neutrophils Above (baseline) - below (Day 85)	0			
Platelets Above (baseline) - below (Day 85)	0			
WBC Above (baseline) - below (Day 85)	0			
ALT Below (baseline) - within (Day 85)	0			
AST Below (baseline) - within (Day 85)	0			
Creatinine Below (baseline) - within (Day 85)	0			
Urea Nitrogen Below (baseline) - within (Day 85)	0			
Basophils Below (baseline) - within (Day 85)	0			
Eosinophils Below (baseline) - within (Day 85)	0			
Hemoglobin Below (baseline) - within (Day 85)	1			
Lymphocytes Below (baseline) - within (Day 85)	0			
Monocytes Below (baseline) - within (Day 85)	0			
Neutrophils Below (baseline) - within (Day 85)	0			
Platelets Below (baseline) - within (Day 85)	0			
WBC Below (baseline) - within (Day 85)	0			
ALT Within (baseline) - within (Day 85)	10			
AST Within (baseline) - within (Day 85)	10			
Creatinine Within (baseline) - within (Day 85)	7			
Urea Nitrogen Within (baseline) - within (Day 85)	10			
Basophils Within (baseline) - within (Day 85)	10			

Eosinophils Within (baseline) - within (Day 85)	10			
Hemoglobin Within (baseline) - within (Day 85)	9			
Lymphocytes Within (baseline) - within (Day 85)	10			
Monocytes Within (baseline) - within (Day 85)	10			
Neutrophils Within (baseline) - within (Day 85)	6			
Platelets Within (baseline) - within (Day 85)	10			
WBC Within (baseline) - within (Day 85)	7			
ALT Above (baseline) - within (Day 85)	0			
AST Above (baseline) - within (Day 85)	0			
Creatinine Above (baseline) - within (Day 85)	1			
Urea Nitrogen Above (baseline) - within (Day 85)	0			
Basophils Above (baseline) - within (Day 85)	0			
Eosinophils Above (baseline) - within (Day 85)	0			
Hemoglobin Above (baseline) - within (Day 85)	0			
Lymphocytes Above (baseline) - within (Day 85)	0			
Monocytes Above (baseline) - within (Day 85)	0			
Neutrophils Above (baseline) - within (Day 85)	4			
Platelets Above (baseline) - within (Day 85)	0			
WBC Above (baseline) - within (Day 85)	3			
ALT Below (baseline) - above (Day 85)	0			
AST Below (baseline) - above (Day 85)	0			
Creatinine Below (baseline) - above (Day 85)	0			
Urea Nitrogen Below (baseline) - above (Day 85)	0			
Basophils Below (baseline) - above (Day 85)	0			
Eosinophils Below (baseline) - above (Day 85)	0			
Hemoglobin Below (baseline) - above (Day 85)	0			
Lymphocytes Below (baseline) - above (Day 85)	0			
Monocytes Below (baseline) - above (Day 85)	0			
Neutrophils Below (baseline) - above (Day 85)	0			
Platelets Below (baseline) - above (Day 85)	0			
WBC Below (baseline) - above (Day 85)	0			
ALT Within (baseline) - above (Day 85)	0			
AST Within (baseline) - above (Day 85)	0			
Creatinine Within (baseline) - above (Day 85)	1			

Urea Nitrogen Within (baseline) - above (Day 85)	0			
Basophils Within (baseline) - above (Day 85)	0			
Eosinophils Within (baseline) - above (Day 85)	0			
Hemoglobin Within (baseline) - above (Day 85)	0			
Lymphocytes Within (baseline) - above (Day 85)	0			
Monocytes Within (baseline) - above (Day 85)	0			
Neutrophils Within (baseline) - above (Day 85)	0			
Platelets Within (baseline) - above (Day 85)	0			
WBC Within (baseline) - above (Day 85)	0			
ALT Above (baseline) - above (Day 85)	0			
AST Above (baseline) - above (Day 85)	0			
Creatinine Above (baseline) - above (Day 85)	1			
Urea Nitrogen Above (baseline) - above (Day 85)	0			
Basophils Above (baseline) - above (Day 85)	0			
Eosinophils Above (baseline) - above (Day 85)	0			
Hemoglobin Above (baseline) - above (Day 85)	0			
Lymphocytes Above (baseline) - above (Day 85)	0			
Monocytes Above (baseline) - above (Day 85)	0			
Neutrophils Above (baseline) - above (Day 85)	0			
Platelets Above (baseline) - above (Day 85)	0			
WBC Above (baseline) - above (Day 85)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 197

End point title	Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 197 ^{[35][36]}
-----------------	--

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 197 (28 days after the third study intervention administration) compared to Baseline (Day 169)

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: <The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	13	14
Units: Participants				
ALT Below (baseline) - below (Day 197)	0	0	0	0
AST Below (baseline) - below (Day 197)	0	0	0	0
Creatinine Below (baseline) - below (Day 197)	0	0	0	0
Urea Nitrogen Below (baseline) - below (Day 197)	0	0	0	0
Basophils Below (baseline) - below (Day 197)	0	0	0	0
Eosinophils Below (baseline) - below (Day 197)	0	0	0	0
Hemoglobin Below (baseline) - below (Day 197)	0	0	0	0
Lymphocytes Below (baseline) - below (Day 197)	0	0	0	0
Monocytes Below (baseline) - below (Day 197)	0	0	0	0
Neutrophils Below (baseline) - below (Day 197)	0	0	0	0
Platelets Below (baseline) - below (Day 197)	0	0	0	1
WBC Below (baseline) - below (Day 197)	0	0	0	0
ALT Within (baseline) - below (Day 197)	0	0	0	0
AST Within (baseline) - below (Day 197)	0	0	0	0
Creatinine Within (baseline) - below (Day 197)	0	0	0	0
Urea Nitrogen Within (baseline) - below (Day 197)	0	0	0	0
Basophils Within (baseline) - below (Day 197)	0	0	0	0
Eosinophils Within (baseline) - below (Day 197)	0	0	0	0
Hemoglobin Within (baseline) - below (Day 197)	0	0	1	1
Lymphocytes Within (baseline) - below (Day 197)	0	0	0	0
Monocytes Within (baseline) - below (Day 197)	0	0	0	0
Neutrophils Within (baseline) - below (Day 197)	0	0	1	0

Platelets Within (baseline) - below (Day 197)	0	0	0	0
WBC Within (baseline) - below (Day 197)	0	1	1	0
ALT Above (baseline) - below (Day 197)	0	0	0	0
AST Above (baseline) - below (Day 197)	0	0	0	0
Creatinine Above (baseline) - below (Day 197)	0	0	0	0
Urea Nitrogen Above (baseline) - below (Day 197)	0	0	0	0
Basophils Above (baseline) - below (Day 197)	0	0	0	0
Eosinophils Above (baseline) - below (Day 197)	0	0	0	0
Hemoglobin Above (baseline) - below (Day 197)	0	0	0	0
Lymphocytes Above (baseline) - below (Day 197)	0	0	0	0
Monocytes Above (baseline) - below (Day 197)	0	0	0	0
Neutrophils Above (baseline) - below (Day 197)	0	0	0	0
Platelets Above (baseline) - below (Day 197)	0	0	0	0
WBC Above (baseline) - below (Day 197)	0	0	0	0
ALT Below (baseline) - within (Day 197)	0	0	0	0
AST Below (baseline) - within (Day 197)	0	0	0	0
Creatinine Below (baseline) - within (Day 197)	0	0	0	0
Urea Nitrogen Below (baseline) - within (Day 197)	1	0	0	0
Basophils Below (baseline) - within (Day 197)	0	0	0	0
Eosinophils Below (baseline) - within (Day 197)	0	0	0	0
Hemoglobin Below (baseline) - within (Day 197)	0	0	0	0
Lymphocytes Below (baseline) - within (Day 197)	0	0	0	0
Monocytes Below (baseline) - within (Day 197)	0	0	0	0
Neutrophils Below (baseline) - within (Day 197)	0	0	0	0
Platelets Below (baseline) - within (Day 197)	0	0	0	0
WBC Below (baseline) - within (Day 197)	0	0	0	0
ALT Within (baseline) - within (Day 197)	4	3	10	14
AST Within (baseline) - within (Day 197)	4	3	12	13
Creatinine Within (baseline) - within (Day 197)	2	3	11	13
Urea Nitrogen Within (baseline) - within (Day 197)	3	3	13	13
Basophils Within (baseline) - within (Day 197)	4	3	13	14
Eosinophils Within (baseline) - within (Day 197)	4	3	13	14
Hemoglobin Within (baseline) - within (Day 197)	4	3	11	12

Lymphocytes Within (baseline) - within (Day 197)	4	3	13	13
Monocytes Within (baseline) - within (Day 197)	4	3	13	14
Neutrophils Within (baseline) - within (Day 197)	3	3	9	11
Platelets Within (baseline) - within (Day 197)	3	2	11	13
WBC Within (baseline) - within (Day 197)	4	2	12	12
ALT Above (baseline) - within (Day 197)	0	0	1	0
AST Above (baseline) - within (Day 197)	0	0	0	0
Creatinine Above (baseline) - within (Day 197)	0	0	0	0
Urea Nitrogen Above (baseline) - within (Day 197)	0	0	0	0
Basophils Above (baseline) - within (Day 197)	0	0	0	0
Eosinophils Above (baseline) - within (Day 197)	0	0	0	0
Hemoglobin Above (baseline) - within (Day 197)	0	0	0	0
Lymphocytes Above (baseline) - within (Day 197)	0	0	0	1
Monocytes Above (baseline) - within (Day 197)	0	0	0	0
Neutrophils Above (baseline) - within (Day 197)	1	0	2	1
Platelets Above (baseline) - within (Day 197)	0	0	1	0
WBC Above (baseline) - within (Day 197)	0	0	0	1
ALT Below (baseline) - above (Day 197)	0	0	0	0
AST Below (baseline) - above (Day 197)	0	0	0	0
Creatinine Below (baseline) - above (Day 197)	0	0	0	0
Urea Nitrogen Below (baseline) - above (Day 197)	0	0	0	0
Basophils Below (baseline) - above (Day 197)	0	0	0	0
Eosinophils Below (baseline) - above (Day 197)	0	0	0	0
Hemoglobin Below (baseline) - above (Day 197)	0	0	0	0
Lymphocytes Below (baseline) - above (Day 197)	0	0	0	0
Monocytes Below (baseline) - above (Day 197)	0	0	0	0
Neutrophils Below (baseline) - above (Day 197)	0	0	0	0
Platelets Below (baseline) - above (Day 197)	0	0	0	0
WBC Below (baseline) - above (Day 197)	0	0	0	0
ALT Within (baseline) - above (Day 197)	0	0	2	0
AST Within (baseline) - above (Day 197)	0	0	0	1
Creatinine Within (baseline) - above (Day 197)	1	0	1	0

Urea Nitrogen Within (baseline) - above (Day 197)	0	0	0	0
Basophils Within (baseline) - above (Day 197)	0	0	0	0
Eosinophils Within (baseline) - above (Day 197)	0	0	0	0
Hemoglobin Within (baseline) - above (Day 197)	0	0	1	1
Lymphocytes Within (baseline) - above (Day 197)	0	0	0	0
Monocytes Within (baseline) - above (Day 197)	0	0	0	0
Neutrophils Within (baseline) - above (Day 197)	0	0	0	1
Platelets Within (baseline) - above (Day 197)	1	1	0	0
WBC Within (baseline) - above (Day 197)	0	0	0	1
ALT Above (baseline) - above (Day 197)	0	0	0	0
AST Above (baseline) - above (Day 197)	0	0	1	0
Creatinine Above (baseline) - above (Day 197)	1	0	1	1
Urea Nitrogen Above (baseline) - above (Day 197)	0	0	0	1
Basophils Above (baseline) - above (Day 197)	0	0	0	0
Eosinophils Above (baseline) - above (Day 197)	0	0	0	0
Hemoglobin Above (baseline) - above (Day 197)	0	0	0	0
Lymphocytes Above (baseline) - above (Day 197)	0	0	0	0
Monocytes Above (baseline) - above (Day 197)	0	0	0	0
Neutrophils Above (baseline) - above (Day 197)	0	0	1	1
Platelets Above (baseline) - above (Day 197)	0	0	1	0
WBC Above (baseline) - above (Day 197)	0	0	0	0

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
ALT Below (baseline) - below (Day 197)	0			
AST Below (baseline) - below (Day 197)	0			
Creatinine Below (baseline) - below (Day 197)	0			
Urea Nitrogen Below (baseline) - below (Day 197)	0			
Basophils Below (baseline) - below (Day 197)	0			
Eosinophils Below (baseline) - below (Day 197)	0			

Hemoglobin Below (baseline) - below (Day 197)	0			
Lymphocytes Below (baseline) - below (Day 197)	0			
Monocytes Below (baseline) - below (Day 197)	0			
Neutrophils Below (baseline) - below (Day 197)	0			
Platelets Below (baseline) - below (Day 197)	0			
WBC Below (baseline) - below (Day 197)	0			
ALT Within (baseline) - below (Day 197)	0			
AST Within (baseline) - below (Day 197)	0			
Creatinine Within (baseline) - below (Day 197)	0			
Urea Nitrogen Within (baseline) - below (Day 197)	0			
Basophils Within (baseline) - below (Day 197)	0			
Eosinophils Within (baseline) - below (Day 197)	0			
Hemoglobin Within (baseline) - below (Day 197)	0			
Lymphocytes Within (baseline) - below (Day 197)	0			
Monocytes Within (baseline) - below (Day 197)	0			
Neutrophils Within (baseline) - below (Day 197)	0			
Platelets Within (baseline) - below (Day 197)	0			
WBC Within (baseline) - below (Day 197)	0			
ALT Above (baseline) - below (Day 197)	0			
AST Above (baseline) - below (Day 197)	0			
Creatinine Above (baseline) - below (Day 197)	0			
Urea Nitrogen Above (baseline) - below (Day 197)	0			
Basophils Above (baseline) - below (Day 197)	0			
Eosinophils Above (baseline) - below (Day 197)	0			
Hemoglobin Above (baseline) - below (Day 197)	0			
Lymphocytes Above (baseline) - below (Day 197)	0			
Monocytes Above (baseline) - below (Day 197)	0			
Neutrophils Above (baseline) - below (Day 197)	0			
Platelets Above (baseline) - below (Day 197)	0			
WBC Above (baseline) - below (Day 197)	0			
ALT Below (baseline) - within (Day 197)	0			
AST Below (baseline) - within (Day 197)	0			
Creatinine Below (baseline) - within (Day 197)	0			

Urea Nitrogen Below (baseline) - within (Day 197)	0			
Basophils Below (baseline) - within (Day 197)	0			
Eosinophils Below (baseline) - within (Day 197)	0			
Hemoglobin Below (baseline) - within (Day 197)	0			
Lymphocytes Below (baseline) - within (Day 197)	0			
Monocytes Below (baseline) - within (Day 197)	0			
Neutrophils Below (baseline) - within (Day 197)	0			
Platelets Below (baseline) - within (Day 197)	0			
WBC Below (baseline) - within (Day 197)	0			
ALT Within (baseline) - within (Day 197)	10			
AST Within (baseline) - within (Day 197)	10			
Creatinine Within (baseline) - within (Day 197)	7			
Urea Nitrogen Within (baseline) - within (Day 197)	10			
Basophils Within (baseline) - within (Day 197)	10			
Eosinophils Within (baseline) - within (Day 197)	10			
Hemoglobin Within (baseline) - within (Day 197)	9			
Lymphocytes Within (baseline) - within (Day 197)	10			
Monocytes Within (baseline) - within (Day 197)	10			
Neutrophils Within (baseline) - within (Day 197)	9			
Platelets Within (baseline) - within (Day 197)	10			
WBC Within (baseline) - within (Day 197)	10			
ALT Above (baseline) - within (Day 197)	0			
AST Above (baseline) - within (Day 197)	0			
Creatinine Above (baseline) - within (Day 197)	0			
Urea Nitrogen Above (baseline) - within (Day 197)	0			
Basophils Above (baseline) - within (Day 197)	0			
Eosinophils Above (baseline) - within (Day 197)	0			
Hemoglobin Above (baseline) - within (Day 197)	0			
Lymphocytes Above (baseline) - within (Day 197)	0			
Monocytes Above (baseline) - within (Day 197)	0			
Neutrophils Above (baseline) - within (Day 197)	0			
Platelets Above (baseline) - within (Day 197)	0			

WBC Above (baseline) - within (Day 197)	0			
ALT Below (baseline) - above (Day 197)	0			
AST Below (baseline) - above (Day 197)	0			
Creatinine Below (baseline) - above (Day 197)	0			
Urea Nitrogen Below (baseline) - above (Day 197)	0			
Basophils Below (baseline) - above (Day 197)	0			
Eosinophils Below (baseline) - above (Day 197)	0			
Hemoglobin Below (baseline) - above (Day 197)	0			
Lymphocytes Below (baseline) - above (Day 197)	0			
Monocytes Below (baseline) - above (Day 197)	0			
Neutrophils Below (baseline) - above (Day 197)	0			
Platelets Below (baseline) - above (Day 197)	0			
WBC Below (baseline) - above (Day 197)	0			
ALT Within (baseline) - above (Day 197)	0			
AST Within (baseline) - above (Day 197)	0			
Creatinine Within (baseline) - above (Day 197)	1			
Urea Nitrogen Within (baseline) - above (Day 197)	0			
Basophils Within (baseline) - above (Day 197)	0			
Eosinophils Within (baseline) - above (Day 197)	0			
Hemoglobin Within (baseline) - above (Day 197)	0			
Lymphocytes Within (baseline) - above (Day 197)	0			
Monocytes Within (baseline) - above (Day 197)	0			
Neutrophils Within (baseline) - above (Day 197)	0			
Platelets Within (baseline) - above (Day 197)	0			
WBC Within (baseline) - above (Day 197)	0			
ALT Above (baseline) - above (Day 197)	0			
AST Above (baseline) - above (Day 197)	0			
Creatinine Above (baseline) - above (Day 197)	2			
Urea Nitrogen Above (baseline) - above (Day 197)	0			
Basophils Above (baseline) - above (Day 197)	0			
Eosinophils Above (baseline) - above (Day 197)	0			
Hemoglobin Above (baseline) - above (Day 197)	1			

Lymphocytes Above (baseline) - above (Day 197)	0			
Monocytes Above (baseline) - above (Day 197)	0			
Neutrophils Above (baseline) - above (Day 197)	1			
Platelets Above (baseline) - above (Day 197)	0			
WBC Above (baseline) - above (Day 197)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any solicited administration site events after the first study intervention administration

End point title	Stage 2: Number of participants with any solicited administration site events after the first study intervention administration ^[37] ^[38]
-----------------	---

End point description:

The solicited administration site events included redness (Erythema), pain and swelling. Data for solicited administration site events is presented for each intervention administered in each arm group. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received first dose of the study intervention and who had solicited safety data in the 7 days following first intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants				
Redness, iNTS-TCV full dose	2	0	0	
Redness, saline	0	0	0	
Redness, TCV full dose	0	3	0	
Redness, iNTS-GMMA full dose	0	7	0	
Redness, control	0	0	0	
Pain, iNTS-TCV full dose	38	0	0	
Pain, saline	16	0	5	
Pain, TCV full dose	0	20	0	

Pain, iNTS-GMMA full dose	0	41	0	
Pain, control	0	0	6	
Swelling, iNTS-TCV full dose	7	0	0	
Swelling, saline	1	0	0	
Swelling, TCV full dose	0	2	0	
Swelling, iNTS-GMMA full dose	0	10	0	
Swelling, control	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any solicited administration site events after the second study intervention administration

End point title	Stage 2: Number of participants with any solicited administration site events after the second study intervention administration ^{[39][40]}
-----------------	--

End point description:

The solicited administration site events included redness (Erythema), pain and swelling. Data for solicited administration site events is presented for each intervention administered in each arm group. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received second dose of the study intervention and who had solicited safety data in the 7 days following second intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	43	15	
Units: Participants				
Redness, iNTS-TCV full dose	1	0	0	
Redness, saline	1	0	0	
Redness, TCV full dose	0	2	0	
Redness, iNTS-GMMA full dose	0	3	0	
Redness, control	0	0	1	
Pain, iNTS-TCV full dose	35	0	0	
Pain, saline	14	0	5	
Pain, TCV full dose	0	24	0	
Pain, iNTS-GMMA full dose	0	41	0	

Pain, control	0	0	9	
Swelling, iNTS-TCV full dose	6	0	0	
Swelling, saline	2	0	0	
Swelling, TCV full dose	0	6	0	
Swelling, iNTS-GMMA full dose	0	11	0	
Swelling, control	0	0	2	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any solicited administration site events after the third study intervention administration

End point title	Stage 2: Number of participants with any solicited administration site events after the third study intervention administration ^[41] ^[42]
-----------------	---

End point description:

The solicited administration site events included redness (Erythema), pain and swelling. Data for solicited administration site events is presented for each intervention administered in each arm group. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received third dose of the study intervention and who had solicited safety data in the 7 days following third intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	38	14	
Units: Participants				
Redness, iNTS-TCV full dose	4	0	0	
Redness, saline	0	0	0	
Redness, TCV full dose	0	1	0	
Redness, iNTS-GMMA full dose	0	3	0	
Redness, control	0	0	0	
Pain, iNTS-TCV full dose	32	0	0	
Pain, saline	10	0	6	
Pain, TCV full dose	0	19	0	
Pain, iNTS-GMMA full dose	0	35	0	
Pain, control	0	0	8	

Swelling, iNTS-TCV full dose	5	0	0	
Swelling, saline	2	0	1	
Swelling, TCV full dose	0	2	0	
Swelling, iNTS-GMMA full dose	0	9	0	
Swelling, control	0	0	1	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any solicited systemic events after the first study intervention administration

End point title	Stage 2: Number of participants with any solicited systemic events after the first study intervention administration ^[43] ^[44]
-----------------	--

End point description:

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain) and fever (pyrexia). Fever is defined as body temperature ≥ 38.0 degrees Celsius ($^{\circ}\text{C}$). The preferred location for measuring temperature is the axilla. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received first dose of the study intervention and who had solicited safety data in the 7 days following first intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants				
Arthralgia	12	10	3	
Fatigue	23	20	4	
Headache	26	24	5	
Myalgia	23	21	3	
Fever	8	6	0	

Statistical analyses

Primary: Stage 2: Number of participants with any solicited systemic events after the second study intervention administration

End point title	Stage 2: Number of participants with any solicited systemic events after the second study intervention administration ^[45] ^[46]
-----------------	---

End point description:

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain) and fever (pyrexia). Fever is defined as body temperature ≥ 38.0 degrees Celsius ($^{\circ}\text{C}$). The preferred location for measuring temperature is the axilla. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received second dose of the study intervention and who had solicited safety data in the 7 days following second intervention. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)

Notes:

[45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	43	15	
Units: Participants				
Arthralgia	11	11	5	
Fatigue	18	24	4	
Headache	22	26	5	
Myalgia	18	20	5	
Fever	5	5	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any solicited systemic events after the third study intervention administration

End point title	Stage 2: Number of participants with any solicited systemic events after the third study intervention administration ^[47] ^[48]
-----------------	--

End point description:

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain) and fever (pyrexia). Fever is defined as body temperature ≥ 38.0 degrees Celsius ($^{\circ}\text{C}$). The preferred location for measuring temperature is the axilla. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Solicited safety set, which included all participants who received third dose of the study intervention and who had solicited safety data in the 7 days following third intervention. Only participants with data available at the mentioned timepoints were

included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)

Notes:

[47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	38	14	
Units: Participants				
Arthralgia	13	15	3	
Fatigue	18	18	2	
Headache	21	23	2	
Myalgia	17	18	4	
Fever	4	9	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any unsolicited AE after the first study intervention administration

End point title	Stage 2: Number of participants with any unsolicited AE after the first study intervention administration ^[49] ^[50]
-----------------	---

End point description:

An unsolicited AE is an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the unsolicited safety set, which included all participants who received the first dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 28 days post vaccination (day of administration and 27 subsequent days post-first vaccination on Day 1)

Notes:

[49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is

presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants	21	24	8	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any unsolicited AE after the second study intervention administration

End point title	Stage 2: Number of participants with any unsolicited AE after the second study intervention administration ^[51] ^[52]
-----------------	--

End point description:

An unsolicited AE is an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the unsolicited safety set, which included all participants who received the second dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 28 days post vaccination (day of administration and 27 subsequent days post-second vaccination on Day 57)

Notes:

[51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	43	15	
Units: Participants	13	17	3	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any unsolicited AE after the third study intervention administration

End point title	Stage 2: Number of participants with any unsolicited AE after the third study intervention administration ^{[53][54]}
-----------------	---

End point description:

An unsolicited AE is an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the unsolicited safety set, which included all participants who received the third dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Within 28 days post vaccination (day of administration and 27 subsequent days post-third vaccination on Day 169)

Notes:

[53] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	38	14	
Units: Participants	13	12	1	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of participants with any SAEs

End point title	Stage 2: Number of participants with any SAEs ^{[55][56]}
-----------------	---

End point description:

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)

Notes:

[55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants	0	1	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants with any AEs/SAEs Leading to Withdrawal from the Study

End point title	Stage 2: Number of Participants with any AEs/SAEs Leading to Withdrawal from the Study ^[57] ^[58]
-----------------	--

End point description:

Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

From first study intervention administration (Day 1) up to 28 days after the third study intervention (Day 197)

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants with any AEs/SAEs Leading to Withholding Further Study Intervention Administration

End point title	Stage 2: Number of Participants with any AEs/SAEs Leading to Withholding Further Study Intervention Administration ^[59] ^[60]
-----------------	--

End point description:

AEs/SAEs that lead to withholding of the study intervention administration were considered under this outcome measure. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

From first study intervention administration (Day 1) up to 28 days after the third study intervention (Day 197)

Notes:

[59] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 8

End point title	Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 8 ^[61] ^[62]
-----------------	--

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 8 (7 days after the first study intervention administration) compared to Baseline (Day 1)

Notes:

[61] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants				
ALT Below (baseline) - below (Day 8)	0	0	0	
AST Below (baseline) - below (Day 8)	0	0	0	
Creatinine Below (baseline) - below (Day 8)	2	3	0	
Urea Nitrogen Below (baseline) - below (Day 8)	6	5	1	
Basophils Below (baseline) - below (Day 8)	0	0	0	
Eosinophils Below (baseline) - below (Day 8)	0	0	0	
Hemoglobin Below (baseline) - below (Day 8)	1	0	0	
Lymphocytes Below (baseline) - below (Day 8)	0	0	0	
Monocytes Below (baseline) - below (Day 8)	0	0	0	
Neutrophils Below (baseline) - below (Day 8)	0	0	0	
Platelets Below (baseline) - below (Day 8)	1	0	0	
WBC Below (baseline) - below (Day 8)	0	0	0	
ALT Within (baseline) - below (Day 8)	2	1	0	
AST Within (baseline) - below (Day 8)	0	0	0	
Creatinine Within (baseline) - below (Day 8)	1	1	1	
Urea Nitrogen Within (baseline) - below (Day 8)	11	4	0	
Basophils Within (baseline) - below (Day 8)	0	0	0	
Eosinophils Within (baseline) - below (Day 8)	0	0	0	
Hemoglobin Within (baseline) - below (Day 8)	1	1	0	
Lymphocytes Within (baseline) - below (Day 8)	0	0	0	
Monocytes Within (baseline) - below (Day 8)	0	0	0	
Neutrophils Within (baseline) - below (Day 8)	0	0	0	
Platelets Within (baseline) - below (Day 8)	0	0	0	
WBC Within (baseline) - below (Day 8)	0	1	0	
ALT Above (baseline) - below (Day 8)	0	0	0	
AST Above (baseline) - below (Day 8)	0	0	0	
Creatinine Above (baseline) - below (Day 8)	0	0	0	
Urea Nitrogen Above (baseline) - below (Day 8)	0	0	0	

Basophils Above (baseline) - below (Day 8)	0	0	0	
Eosinophils Above (baseline) - below (Day 8)	0	0	0	
Hemoglobin Above (baseline) - below (Day 8)	0	0	0	
Lymphocytes Above (baseline) - below (Day 8)	0	0	0	
Monocytes Above (baseline) - below (Day 8)	0	0	0	
Neutrophils Above (baseline) - below (Day 8)	0	0	0	
Platelets Above (baseline) - below (Day 8)	0	0	0	
WBC Above (baseline) - below (Day 8)	0	0	0	
ALT Below (baseline) - within (Day 8)	0	0	0	
AST Below (baseline) - within (Day 8)	1	0	0	
Creatinine Below (baseline) - within (Day 8)	1	0	1	
Urea Nitrogen Below (baseline) - within (Day 8)	6	7	3	
Basophils Below (baseline) - within (Day 8)	0	0	0	
Eosinophils Below (baseline) - within (Day 8)	0	0	0	
Hemoglobin Below (baseline) - within (Day 8)	0	0	0	
Lymphocytes Below (baseline) - within (Day 8)	0	0	0	
Monocytes Below (baseline) - within (Day 8)	0	0	0	
Neutrophils Below (baseline) - within (Day 8)	0	0	0	
Platelets Below (baseline) - within (Day 8)	0	1	0	
WBC Below (baseline) - within (Day 8)	0	0	0	
ALT Within (baseline) - within (Day 8)	36	35	13	
AST Within (baseline) - within (Day 8)	37	43	12	
Creatinine Within (baseline) - within (Day 8)	41	41	13	
Urea Nitrogen Within (baseline) - within (Day 8)	22	29	11	
Basophils Within (baseline) - within (Day 8)	45	44	15	
Eosinophils Within (baseline) - within (Day 8)	44	45	15	
Hemoglobin Within (baseline) - within (Day 8)	38	39	11	
Lymphocytes Within (baseline) - within (Day 8)	43	43	13	
Monocytes Within (baseline) - within (Day 8)	39	44	15	
Neutrophils Within (baseline) - within (Day 8)	41	42	15	
Platelets Within (baseline) - within (Day 8)	35	32	11	
WBC Within (baseline) - within (Day 8)	41	41	14	
ALT Above (baseline) - within (Day 8)	3	5	2	
AST Above (baseline) - within (Day 8)	2	2	3	

Creatinine Above (baseline) - within (Day 8)	0	0	0	
Urea Nitrogen Above (baseline) - within (Day 8)	0	0	0	
Basophils Above (baseline) - within (Day 8)	0	1	0	
Eosinophils Above (baseline) - within (Day 8)	0	0	0	
Hemoglobin Above (baseline) - within (Day 8)	1	2	0	
Lymphocytes Above (baseline) - within (Day 8)	0	0	2	
Monocytes Above (baseline) - within (Day 8)	0	0	0	
Neutrophils Above (baseline) - within (Day 8)	1	1	0	
Platelets Above (baseline) - within (Day 8)	0	1	1	
WBC Above (baseline) - within (Day 8)	0	2	1	
ALT Below (baseline) - above (Day 8)	0	0	0	
AST Below (baseline) - above (Day 8)	0	0	0	
Creatinine Below (baseline) - above (Day 8)	0	0	0	
Urea Nitrogen Below (baseline) - above (Day 8)	0	0	0	
Basophils Below (baseline) - above (Day 8)	0	0	0	
Eosinophils Below (baseline) - above (Day 8)	0	0	0	
Hemoglobin Below (baseline) - above (Day 8)	0	0	0	
Lymphocytes Below (baseline) - above (Day 8)	0	0	0	
Monocytes Below (baseline) - above (Day 8)	0	0	0	
Neutrophils Below (baseline) - above (Day 8)	0	0	0	
Platelets Below (baseline) - above (Day 8)	0	0	0	
WBC Below (baseline) - above (Day 8)	0	0	0	
ALT Within (baseline) - above (Day 8)	2	2	0	
AST Within (baseline) - above (Day 8)	3	0	0	
Creatinine Within (baseline) - above (Day 8)	0	0	0	
Urea Nitrogen Within (baseline) - above (Day 8)	0	0	0	
Basophils Within (baseline) - above (Day 8)	0	0	0	
Eosinophils Within (baseline) - above (Day 8)	1	0	0	
Hemoglobin Within (baseline) - above (Day 8)	1	1	2	
Lymphocytes Within (baseline) - above (Day 8)	1	2	0	
Monocytes Within (baseline) - above (Day 8)	6	1	0	
Neutrophils Within (baseline) - above (Day 8)	3	1	0	
Platelets Within (baseline) - above (Day 8)	5	5	1	
WBC Within (baseline) - above (Day 8)	3	1	0	

ALT Above (baseline) - above (Day 8)	2	2	0	
AST Above (baseline) - above (Day 8)	2	0	0	
Creatinine Above (baseline) - above (Day 8)	0	0	0	
Urea Nitrogen Above (baseline) - above (Day 8)	0	0	0	
Basophils Above (baseline) - above (Day 8)	0	0	0	
Eosinophils Above (baseline) - above (Day 8)	0	0	0	
Hemoglobin Above (baseline) - above (Day 8)	3	2	2	
Lymphocytes Above (baseline) - above (Day 8)	1	0	0	
Monocytes Above (baseline) - above (Day 8)	0	0	0	
Neutrophils Above (baseline) - above (Day 8)	0	1	0	
Platelets Above (baseline) - above (Day 8)	4	6	2	
WBC Above (baseline) - above (Day 8)	1	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 64

End point title	Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 64 ^[63] ^[64]
-----------------	---

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 64 (7 days after the second study intervention administration) compared to Baseline (Day 57)

Notes:

[63] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	43	15	
Units: Participants				
ALT Below (baseline) - below (Day 64)	0	0	0	
AST Below (baseline) - below (Day 64)	0	0	0	
Creatinine Below (baseline) - below (Day 64)	3	3	0	
Urea Nitrogen Below (baseline) - below (Day 64)	6	5	4	
Basophils Below (baseline) - below (Day 64)	0	0	0	
Eosinophils Below (baseline) - below (Day 64)	0	0	0	
Hemoglobin Below (baseline) - below (Day 64)	1	0	0	
Lymphocytes Below (baseline) - below (Day 64)	0	0	0	
Monocytes Below (baseline) - below (Day 64)	0	0	0	
Neutrophils Below (baseline) - below (Day 64)	0	0	0	
Platelets Below (baseline) - below (Day 64)	1	0	0	
WBC Below (baseline) - below (Day 64)	0	0	0	
ALT Within (baseline) - below (Day 64)	1	1	0	
AST Within (baseline) - below (Day 64)	0	0	0	
Creatinine Within (baseline) - below (Day 64)	1	2	0	
Urea Nitrogen Within (baseline) - below (Day 64)	4	8	1	
Basophils Within (baseline) - below (Day 64)	0	0	0	
Eosinophils Within (baseline) - below (Day 64)	0	0	0	
Hemoglobin Within (baseline) - below (Day 64)	0	1	0	
Lymphocytes Within (baseline) - below (Day 64)	0	0	0	
Monocytes Within (baseline) - below (Day 64)	0	0	0	
Neutrophils Within (baseline) - below (Day 64)	0	1	0	
Platelets Within (baseline) - below (Day 64)	0	0	0	
WBC Within (baseline) - below (Day 64)	1	0	0	
ALT Above (baseline) - below (Day 64)	0	0	0	
AST Above (baseline) - below (Day 64)	0	0	0	
Creatinine Above (baseline) - below (Day 64)	0	0	0	
Urea Nitrogen Above (baseline) - below (Day 64)	0	0	0	
Basophils Above (baseline) - below (Day 64)	0	0	0	
Eosinophils Above (baseline) - below (Day 64)	0	0	0	
Hemoglobin Above (baseline) - below (Day 64)	0	0	0	

Lymphocytes Above (baseline) - below (Day 64)	0	0	0	
Monocytes Above (baseline) - below (Day 64)	0	0	0	
Neutrophils Above (baseline) - below (Day 64)	0	0	0	
Platelets Above (baseline) - below (Day 64)	0	0	0	
WBC Above (baseline) - below (Day 64)	0	0	0	
ALT Below (baseline) - within (Day 64)	1	0	0	
AST Below (baseline) - within (Day 64)	0	0	0	
Creatinine Below (baseline) - within (Day 64)	0	4	1	
Urea Nitrogen Below (baseline) - within (Day 64)	9	2	2	
Basophils Below (baseline) - within (Day 64)	0	0	0	
Eosinophils Below (baseline) - within (Day 64)	0	0	0	
Hemoglobin Below (baseline) - within (Day 64)	1	0	0	
Lymphocytes Below (baseline) - within (Day 64)	0	0	0	
Monocytes Below (baseline) - within (Day 64)	0	0	0	
Neutrophils Below (baseline) - within (Day 64)	0	0	0	
Platelets Below (baseline) - within (Day 64)	0	0	0	
WBC Below (baseline) - within (Day 64)	0	0	0	
ALT Within (baseline) - within (Day 64)	38	35	12	
AST Within (baseline) - within (Day 64)	40	39	11	
Creatinine Within (baseline) - within (Day 64)	41	34	14	
Urea Nitrogen Within (baseline) - within (Day 64)	26	28	8	
Basophils Within (baseline) - within (Day 64)	44	43	15	
Eosinophils Within (baseline) - within (Day 64)	40	43	15	
Hemoglobin Within (baseline) - within (Day 64)	37	37	13	
Lymphocytes Within (baseline) - within (Day 64)	43	42	15	
Monocytes Within (baseline) - within (Day 64)	44	41	15	
Neutrophils Within (baseline) - within (Day 64)	41	39	15	
Platelets Within (baseline) - within (Day 64)	34	35	12	
WBC Within (baseline) - within (Day 64)	40	41	15	
ALT Above (baseline) - within (Day 64)	2	4	0	
AST Above (baseline) - within (Day 64)	1	4	0	
Creatinine Above (baseline) - within (Day 64)	0	0	0	
Urea Nitrogen Above (baseline) - within (Day 64)	0	0	0	
Basophils Above (baseline) - within (Day 64)	1	0	0	

Eosinophils Above (baseline) - within (Day 64)	1	0	0	
Hemoglobin Above (baseline) - within (Day 64)	1	2	0	
Lymphocytes Above (baseline) - within (Day 64)	0	0	0	
Monocytes Above (baseline) - within (Day 64)	1	1	0	
Neutrophils Above (baseline) - within (Day 64)	2	1	0	
Platelets Above (baseline) - within (Day 64)	1	0	0	
WBC Above (baseline) - within (Day 64)	2	0	0	
ALT Below (baseline) - above (Day 64)	0	0	0	
AST Below (baseline) - above (Day 64)	0	0	0	
Creatinine Below (baseline) - above (Day 64)	0	0	0	
Urea Nitrogen Below (baseline) - above (Day 64)	0	0	0	
Basophils Below (baseline) - above (Day 64)	0	0	0	
Eosinophils Below (baseline) - above (Day 64)	0	0	0	
Hemoglobin Below (baseline) - above (Day 64)	0	0	0	
Lymphocytes Below (baseline) - above (Day 64)	0	0	0	
Monocytes Below (baseline) - above (Day 64)	0	0	0	
Neutrophils Below (baseline) - above (Day 64)	0	0	0	
Platelets Below (baseline) - above (Day 64)	0	0	0	
WBC Below (baseline) - above (Day 64)	0	0	0	
ALT Within (baseline) - above (Day 64)	2	1	1	
AST Within (baseline) - above (Day 64)	1	0	1	
Creatinine Within (baseline) - above (Day 64)	0	0	0	
Urea Nitrogen Within (baseline) - above (Day 64)	0	0	0	
Basophils Within (baseline) - above (Day 64)	0	0	0	
Eosinophils Within (baseline) - above (Day 64)	1	0	0	
Hemoglobin Within (baseline) - above (Day 64)	1	0	0	
Lymphocytes Within (baseline) - above (Day 64)	2	1	0	
Monocytes Within (baseline) - above (Day 64)	0	1	0	
Neutrophils Within (baseline) - above (Day 64)	1	1	0	
Platelets Within (baseline) - above (Day 64)	3	3	0	
WBC Within (baseline) - above (Day 64)	1	2	0	
ALT Above (baseline) - above (Day 64)	1	2	2	
AST Above (baseline) - above (Day 64)	3	0	3	
Creatinine Above (baseline) - above (Day 64)	0	0	0	

Urea Nitrogen Above (baseline) - above (Day 64)	0	0	0	
Basophils Above (baseline) - above (Day 64)	0	0	0	
Eosinophils Above (baseline) - above (Day 64)	3	0	0	
Hemoglobin Above (baseline) - above (Day 64)	4	3	2	
Lymphocytes Above (baseline) - above (Day 64)	0	0	0	
Monocytes Above (baseline) - above (Day 64)	0	0	0	
Neutrophils Above (baseline) - above (Day 64)	1	1	0	
Platelets Above (baseline) - above (Day 64)	6	5	3	
WBC Above (baseline) - above (Day 64)	1	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 176

End point title	Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 176 ^[65] ^[66]
-----------------	--

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 176 (7 days after the third study intervention administration) compared to Baseline (Day 169)

Notes:

[65] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	38	14	
Units: Participants				
ALT Below (baseline) - below (Day 176)	0	0	0	

AST Below (baseline) - below (Day 176)	0	0	0	
Creatinine Below (baseline) - below (Day 176)	4	3	1	
Urea Nitrogen Below (baseline) - below (Day 176)	5	5	2	
Basophils Below (baseline) - below (Day 176)	0	0	0	
Eosinophils Below (baseline) - below (Day 176)	0	0	0	
Hemoglobin Below (baseline) - below (Day 176)	2	0	0	
Lymphocytes Below (baseline) - below (Day 176)	0	0	0	
Monocytes Below (baseline) - below (Day 176)	0	0	0	
Neutrophils Below (baseline) - below (Day 176)	0	0	0	
Platelets Below (baseline) - below (Day 176)	1	0	0	
WBC Below (baseline) - below (Day 176)	0	0	0	
ALT Within (baseline) - below (Day 176)	0	0	0	
AST Within (baseline) - below (Day 176)	0	0	0	
Creatinine Within (baseline) - below (Day 176)	3	1	0	
Urea Nitrogen Within (baseline) - below (Day 176)	7	5	5	
Basophils Within (baseline) - below (Day 176)	0	0	0	
Eosinophils Within (baseline) - below (Day 176)	0	0	0	
Hemoglobin Within (baseline) - below (Day 176)	0	0	0	
Lymphocytes Within (baseline) - below (Day 176)	0	0	0	
Monocytes Within (baseline) - below (Day 176)	0	0	0	
Neutrophils Within (baseline) - below (Day 176)	0	0	0	
Platelets Within (baseline) - below (Day 176)	0	0	0	
WBC Within (baseline) - below (Day 176)	0	0	0	
ALT Above (baseline) - below (Day 176)	0	0	0	
AST Above (baseline) - below (Day 176)	0	0	0	
Creatinine Above (baseline) - below (Day 176)	0	0	0	
Urea Nitrogen Above (baseline) - below (Day 176)	0	0	0	
Basophils Above (baseline) - below (Day 176)	0	0	0	
Eosinophils Above (baseline) - below (Day 176)	0	0	0	
Hemoglobin Above (baseline) - below (Day 176)	0	0	0	
Lymphocytes Above (baseline) - below (Day 176)	0	0	0	
Monocytes Above (baseline) - below (Day 176)	0	0	0	

Neutrophils Above (baseline) - below (Day 176)	0	0	0	
Platelets Above (baseline) - below (Day 176)	0	0	0	
WBC Above (baseline) - below (Day 176)	0	0	0	
ALT Below (baseline) - within (Day 176)	0	0	0	
AST Below (baseline) - within (Day 176)	0	0	0	
Creatinine Below (baseline) - within (Day 176)	0	1	0	
Urea Nitrogen Below (baseline) - within (Day 176)	7	0	2	
Basophils Below (baseline) - within (Day 176)	0	0	0	
Eosinophils Below (baseline) - within (Day 176)	0	0	0	
Hemoglobin Below (baseline) - within (Day 176)	0	0	0	
Lymphocytes Below (baseline) - within (Day 176)	0	0	14	
Monocytes Below (baseline) - within (Day 176)	0	0	0	
Neutrophils Below (baseline) - within (Day 176)	0	0	0	
Platelets Below (baseline) - within (Day 176)	0	1	0	
WBC Below (baseline) - within (Day 176)	0	0	0	
ALT Within (baseline) - within (Day 176)	37	34	14	
AST Within (baseline) - within (Day 176)	34	33	13	
Creatinine Within (baseline) - within (Day 176)	35	33	13	
Urea Nitrogen Within (baseline) - within (Day 176)	23	28	5	
Basophils Within (baseline) - within (Day 176)	42	38	14	
Eosinophils Within (baseline) - within (Day 176)	42	38	14	
Hemoglobin Within (baseline) - within (Day 176)	25	28	7	
Lymphocytes Within (baseline) - within (Day 176)	40	36	0	
Monocytes Within (baseline) - within (Day 176)	39	37	14	
Neutrophils Within (baseline) - within (Day 176)	40	35	14	
Platelets Within (baseline) - within (Day 176)	29	24	11	
WBC Within (baseline) - within (Day 176)	41	36	14	
ALT Above (baseline) - within (Day 176)	3	2	0	
AST Above (baseline) - within (Day 176)	3	3	0	
Creatinine Above (baseline) - within (Day 176)	0	0	0	
Urea Nitrogen Above (baseline) - within (Day 176)	0	0	0	
Basophils Above (baseline) - within (Day 176)	0	0	0	

Eosinophils Above (baseline) - within (Day 176)	0	0	0	
Hemoglobin Above (baseline) - within (Day 176)	5	4	3	
Lymphocytes Above (baseline) - within (Day 176)	1	0	0	
Monocytes Above (baseline) - within (Day 176)	1	1	0	
Neutrophils Above (baseline) - within (Day 176)	0	0	0	
Platelets Above (baseline) - within (Day 176)	1	0	0	
WBC Above (baseline) - within (Day 176)	0	0	0	
ALT Below (baseline) - above (Day 176)	0	0	0	
AST Below (baseline) - above (Day 176)	0	0	0	
Creatinine Below (baseline) - above (Day 176)	0	0	0	
Urea Nitrogen Below (baseline) - above (Day 176)	0	0	0	
Basophils Below (baseline) - above (Day 176)	0	0	0	
Eosinophils Below (baseline) - above (Day 176)	0	0	0	
Hemoglobin Below (baseline) - above (Day 176)	0	0	0	
Lymphocytes Below (baseline) - above (Day 176)	0	0	0	
Monocytes Below (baseline) - above (Day 176)	0	0	0	
Neutrophils Below (baseline) - above (Day 176)	0	0	0	
Platelets Below (baseline) - above (Day 176)	0	0	0	
WBC Below (baseline) - above (Day 176)	0	0	0	
ALT Within (baseline) - above (Day 176)	1	2	0	
AST Within (baseline) - above (Day 176)	3	1	0	
Creatinine Within (baseline) - above (Day 176)	0	0	0	
Urea Nitrogen Within (baseline) - above (Day 176)	0	0	0	
Basophils Within (baseline) - above (Day 176)	0	0	0	
Eosinophils Within (baseline) - above (Day 176)	0	0	0	
Hemoglobin Within (baseline) - above (Day 176)	4	2	0	
Lymphocytes Within (baseline) - above (Day 176)	0	1	0	
Monocytes Within (baseline) - above (Day 176)	1	0	0	
Neutrophils Within (baseline) - above (Day 176)	2	1	0	
Platelets Within (baseline) - above (Day 176)	6	4	1	
WBC Within (baseline) - above (Day 176)	1	0	0	
ALT Above (baseline) - above (Day 176)	1	0	0	

AST Above (baseline) - above (Day 176)	2	1	1	
Creatinine Above (baseline) - above (Day 176)	0	0	0	
Urea Nitrogen Above (baseline) - above (Day 176)	0	0	0	
Basophils Above (baseline) - above (Day 176)	0	0	0	
Eosinophils Above (baseline) - above (Day 176)	0	0	0	
Hemoglobin Above (baseline) - above (Day 176)	6	4	4	
Lymphocytes Above (baseline) - above (Day 176)	1	1	0	
Monocytes Above (baseline) - above (Day 176)	1	0	0	
Neutrophils Above (baseline) - above (Day 176)	0	2	0	
Platelets Above (baseline) - above (Day 176)	5	9	2	
WBC Above (baseline) - above (Day 176)	0	2	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 29

End point title	Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 29 ^[67] ^[68]
-----------------	---

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 29 (28 days after the first study intervention administration) compared to Baseline (Day 1)

Notes:

[67] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	45	15	
Units: Participants				
ALT Below (baseline) - below (Day 29)	0	0	0	
AST Below (baseline) - below (Day 29)	1	0	0	
Creatinine Below (baseline) - below (Day 29)	3	2	1	
Urea Nitrogen Below (baseline) - below (Day 29)	4	3	3	
Basophils Below (baseline) - below (Day 29)	0	0	0	
Eosinophils Below (baseline) - below (Day 29)	0	0	0	
Hemoglobin Below (baseline) - below (Day 29)	0	0	0	
Lymphocytes Below (baseline) - below (Day 29)	0	0	0	
Monocytes Below (baseline) - below (Day 29)	0	0	0	
Neutrophils Below (baseline) - below (Day 29)	0	0	0	
Platelets Below (baseline) - below (Day 29)	1	0	0	
WBC elow (baseline) - below (Day 29)	0	0	0	
ALT Within (baseline) - below (Day 29)	3	1	0	
AST Within (baseline) - below (Day 29)	0	0	0	
Creatinine Within (baseline) - below (Day 29)	1	0	0	
Urea Nitrogen Within (baseline) - below (Day 29)	8	6	3	
Basophils Within (baseline) - below (Day 29)	0	0	0	
Eosinophils Within (baseline) - below (Day 29)	0	0	0	
Hemoglobin Within (baseline) - below (Day 29)	1	0	0	
Lymphocytes Within (baseline) - below (Day 29)	0	0	0	
Monocytes Within (baseline) - below (Day 29)	0	0	0	
Neutrophils Within (baseline) - below (Day 29)	1	0	0	
Platelets Within (baseline) - below (Day 29)	0	0	0	
WBC Within (baseline) - below (Day 29)	0	0	1	
ALT Above (baseline) - below (Day 29)	0	0	0	
AST Above (baseline) - below (Day 29)	0	0	0	
Creatinine Above (baseline) - below (Day 29)	0	0	0	
Urea Nitrogen Above (baseline) - below (Day 29)	0	0	0	
Basophils Above (baseline) - below (Day 29)	0	0	0	
Eosinophils Above (baseline) - below (Day 29)	0	0	0	
Hemoglobin Above (baseline) - below (Day 29)	0	0	0	

Lymphocytes Above (baseline) - below (Day 29)	0	0	0	
Monocytes Above (baseline) - below (Day 29)	0	0	0	
Neutrophils Above (baseline) - below (Day 29)	0	0	0	
Platelets Above (baseline) - below (Day 29)	0	0	0	
WBC Above (baseline) - below (Day 29)	0	0	0	
ALT Below (baseline) - within (Day 29)	0	0	0	
AST Below (baseline) - within (Day 29)	0	0	0	
Creatinine Below (baseline) - within (Day 29)	0	1	0	
Urea Nitrogen Below (baseline) - within (Day 29)	8	9	1	
Basophils Below (baseline) - within (Day 29)	0	0	0	
Eosinophils Below (baseline) - within (Day 29)	0	0	0	
Hemoglobin Below (baseline) - within (Day 29)	1	0	0	
Lymphocytes Below (baseline) - within (Day 29)	0	0	0	
Monocytes Below (baseline) - within (Day 29)	0	0	0	
Neutrophils Below (baseline) - within (Day 29)	0	0	0	
Platelets Below (baseline) - within (Day 29)	0	1	0	
WBC Below (baseline) - within (Day 29)	0	0	0	
ALT Within (baseline) - within (Day 29)	35	31	12	
AST Within (baseline) - within (Day 29)	39	41	11	
Creatinine Within (baseline) - within (Day 29)	41	42	14	
Urea Nitrogen Within (baseline) - within (Day 29)	25	27	8	
Basophils Within (baseline) - within (Day 29)	45	44	15	
Eosinophils Within (baseline) - within (Day 29)	45	45	15	
Hemoglobin Within (baseline) - within (Day 29)	38	39	12	
Lymphocytes Within (baseline) - within (Day 29)	44	44	13	
Monocytes Within (baseline) - within (Day 29)	44	45	15	
Neutrophils Within (baseline) - within (Day 29)	41	43	15	
Platelets Within (baseline) - within (Day 29)	39	36	12	
WBC Within (baseline) - within (Day 29)	43	43	13	
ALT Above (baseline) - within (Day 29)	5	5	2	
AST Above (baseline) - within (Day 29)	3	0	1	
Creatinine Above (baseline) - within (Day 29)	0	0	0	
Urea Nitrogen Above (baseline) - within (Day 29)	0	0	0	
Basophils Above (baseline) - within (Day 29)	0	1	0	

Eosinophils Above (baseline) - within (Day 29)	0	0	0	
Hemoglobin Above (baseline) - within (Day 29)	0	1	0	
Lymphocytes Above (baseline) - within (Day 29)	1	0	2	
Monocytes Above (baseline) - within (Day 29)	0	0	0	
Neutrophils Above (baseline) - within (Day 29)	1	1	0	
Platelets Above (baseline) - within (Day 29)	2	2	0	
WBC Above (baseline) - within (Day 29)	0	2	1	
ALT Below (baseline) - above (Day 29)	0	0	0	
AST Below (baseline) - above (Day 29)	0	0	0	
Creatinine Below (baseline) - above (Day 29)	0	0	0	
Urea Nitrogen Below (baseline) - above (Day 29)	0	0	0	
Basophils Below (baseline) - above (Day 29)	0	0	0	
Eosinophils Below (baseline) - above (Day 29)	0	0	0	
Hemoglobin Below (baseline) - above (Day 29)	0	0	0	
Lymphocytes Below (baseline) - above (Day 29)	0	0	0	
Monocytes Below (baseline) - above (Day 29)	0	0	0	
Neutrophils Below (baseline) - above (Day 29)	0	0	0	
Platelets Below (baseline) - above (Day 29)	0	0	0	
WBC Below (baseline) - above (Day 29)	0	0	0	
ALT Within (baseline) - above (Day 29)	2	6	1	
AST Within (baseline) - above (Day 29)	1	2	1	
Creatinine Within (baseline) - above (Day 29)	0	0	0	
Urea Nitrogen Within (baseline) - above (Day 29)	0	0	0	
Basophils Within (baseline) - above (Day 29)	0	0	0	
Eosinophils Within (baseline) - above (Day 29)	0	0	0	
Hemoglobin Within (baseline) - above (Day 29)	1	2	1	
Lymphocytes Within (baseline) - above (Day 29)	0	1	0	
Monocytes Within (baseline) - above (Day 29)	1	0	0	
Neutrophils Within (baseline) - above (Day 29)	2	0	0	
Platelets Within (baseline) - above (Day 29)	1	1	0	
WBC Within (baseline) - above (Day 29)	1	0	0	
ALT Above (baseline) - above (Day 29)	0	2	0	
AST Above (baseline) - above (Day 29)	1	2	2	
Creatinine Above (baseline) - above (Day 29)	0	0	0	

Urea Nitrogen Above (baseline) - above (Day 29)	0	0	0	
Basophils Above (baseline) - above (Day 29)	0	0	0	
Eosinophils Above (baseline) - above (Day 29)	0	0	0	
Hemoglobin Above (baseline) - above (Day 29)	4	3	2	
Lymphocytes Above (baseline) - above (Day 29)	0	0	0	
Monocytes Above (baseline) - above (Day 29)	0	0	0	
Neutrophils Above (baseline) - above (Day 29)	0	1	0	
Platelets Above (baseline) - above (Day 29)	2	5	3	
WBC Above (baseline) - above (Day 29)	1	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 85

End point title	Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 85 ^[69] ^[70]
-----------------	---

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 85 (28 days after the second study intervention administration) compared to Baseline (Day 57)

Notes:

[69] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	43	15	
Units: Participants				
ALT Below (baseline) - below (Day 85)	1	0	0	

AST Below (baseline) - below (Day 85)	0	0	0	
Creatinine Below (baseline) - below (Day 85)	3	4	1	
Urea Nitrogen Below (baseline) - below (Day 85)	9	4	3	
Basophils Below (baseline) - below (Day 85)	0	0	0	
Eosinophils Below (baseline) - below (Day 85)	0	0	0	
Hemoglobin Below (baseline) - below (Day 85)	1	0	0	
Lymphocytes Below (baseline) - below (Day 85)	0	0	0	
Monocytes Below (baseline) - below (Day 85)	0	0	0	
Neutrophils Below (baseline) - below (Day 85)	0	0	0	
Platelets Below (baseline) - below (Day 85)	1	0	0	
WBC Below (baseline) - below (Day 85)	0	0	0	
ALT Within (baseline) - below (Day 85)	0	1	0	
AST Within (baseline) - below (Day 85)	0	0	0	
Creatinine Within (baseline) - below (Day 85)	3	1	1	
Urea Nitrogen Within (baseline) - below (Day 85)	3	6	1	
Basophils Within (baseline) - below (Day 85)	0	0	0	
Eosinophils Within (baseline) - below (Day 85)	0	0	0	
Hemoglobin Within (baseline) - below (Day 85)	0	0	0	
Lymphocytes Within (baseline) - below (Day 85)	0	0	0	
Monocytes Within (baseline) - below (Day 85)	0	0	0	
Neutrophils Within (baseline) - below (Day 85)	0	0	0	
Platelets Within (baseline) - below (Day 85)	1	0	0	
WBC Within (baseline) - below (Day 85)	0	0	0	
ALT Above (baseline) - below (Day 85)	0	0	0	
AST Above (baseline) - below (Day 85)	0	0	0	
Creatinine Above (baseline) - below (Day 85)	0	0	0	
Urea Nitrogen Above (baseline) - below (Day 85)	0	0	0	
Basophils Above (baseline) - below (Day 85)	0	0	0	
Eosinophils Above (baseline) - below (Day 85)	0	0	0	
Hemoglobin Above (baseline) - below (Day 85)	0	0	0	
Lymphocytes Above (baseline) - below (Day 85)	0	0	0	
Monocytes Above (baseline) - below (Day 85)	0	0	0	
Neutrophils Above (baseline) - below (Day 85)	0	0	0	
Platelets Above (baseline) - below (Day 85)	1	0	0	

WBC Above (baseline) - below (Day 85)	0	0	0	
ALT Below (baseline) - within (Day 85)	0	0	0	
AST Below (baseline) - within (Day 85)	0	0	0	
Creatinine Below (baseline) - within (Day 85)	0	3	0	
Urea Nitrogen Below (baseline) - within (Day 85)	6	3	3	
Basophils Below (baseline) - within (Day 85)	0	0	0	
Eosinophils Below (baseline) - within (Day 85)	0	0	0	
Hemoglobin Below (baseline) - within (Day 85)	1	0	0	
Lymphocytes Below (baseline) - within (Day 85)	0	0	0	
Monocytes Below (baseline) - within (Day 85)	0	0	0	
Neutrophils Below (baseline) - within (Day 85)	0	0	0	
Platelets Below (baseline) - within (Day 85)	0	0	0	
WBC Below (baseline) - within (Day 85)	0	0	0	
ALT Within (baseline) - within (Day 85)	39	33	13	
AST Within (baseline) - within (Day 85)	40	36	12	
Creatinine Within (baseline) - within (Day 85)	39	35	13	
Urea Nitrogen Within (baseline) - within (Day 85)	27	30	8	
Basophils Within (baseline) - within (Day 85)	43	43	15	
Eosinophils Within (baseline) - within (Day 85)	41	43	15	
Hemoglobin Within (baseline) - within (Day 85)	36	38	12	
Lymphocytes Within (baseline) - within (Day 85)	43	42	15	
Monocytes Within (baseline) - within (Day 85)	44	42	15	
Neutrophils Within (baseline) - within (Day 85)	41	41	14	
Platelets Within (baseline) - within (Day 85)	33	37	12	
WBC Within (baseline) - within (Day 85)	42	43	15	
ALT Above (baseline) - within (Day 85)	2	6	2	
AST Above (baseline) - within (Day 85)	2	2	1	
Creatinine Above (baseline) - within (Day 85)	0	0	0	
Urea Nitrogen Above (baseline) - within (Day 85)	0	0	0	
Basophils Above (baseline) - within (Day 85)	1	0	0	
Eosinophils Above (baseline) - within (Day 85)	1	0	0	
Hemoglobin Above (baseline) - within (Day 85)	1	2	0	
Lymphocytes Above (baseline) - within (Day 85)	0	0	0	
Monocytes Above (baseline) - within (Day 85)	1	0	0	

Neutrophils Above (baseline) - within (Day 85)	3	1	1	
Platelets Above (baseline) - within (Day 85)	3	1	1	
WBC Above (baseline) - within (Day 85)	3	0	0	
ALT Below (baseline) - above (Day 85)	0	0	0	
AST Below (baseline) - above (Day 85)	0	0	0	
Creatinine Below (baseline) - above (Day 85)	0	0	0	
Urea Nitrogen Below (baseline) - above (Day 85)	0	0	0	
Basophils Below (baseline) - above (Day 85)	0	0	0	
Eosinophils Below (baseline) - above (Day 85)	0	0	0	
Hemoglobin Below (baseline) - above (Day 85)	0	0	0	
Lymphocytes Below (baseline) - above (Day 85)	0	0	0	
Monocytes Below (baseline) - above (Day 85)	0	0	0	
Neutrophils Below (baseline) - above (Day 85)	0	0	0	
Platelets Below (baseline) - above (Day 85)	0	0	0	
WBC Below (baseline) - above (Day 85)	0	0	0	
ALT Within (baseline) - above (Day 85)	2	3	0	
AST Within (baseline) - above (Day 85)	1	3	0	
Creatinine Within (baseline) - above (Day 85)	0	0	0	
Urea Nitrogen Within (baseline) - above (Day 85)	0	0	0	
Basophils Within (baseline) - above (Day 85)	1	0	0	
Eosinophils Within (baseline) - above (Day 85)	0	0	0	
Hemoglobin Within (baseline) - above (Day 85)	2	0	1	
Lymphocytes Within (baseline) - above (Day 85)	2	1	0	
Monocytes Within (baseline) - above (Day 85)	0	0	0	
Neutrophils Within (baseline) - above (Day 85)	1	0	0	
Platelets Within (baseline) - above (Day 85)	3	1	0	
WBC Within (baseline) - above (Day 85)	0	0	0	
ALT Above (baseline) - above (Day 85)	1	0	0	
AST Above (baseline) - above (Day 85)	2	2	2	
Creatinine Above (baseline) - above (Day 85)	0	0	0	
Urea Nitrogen Above (baseline) - above (Day 85)	0	0	0	
Basophils Above (baseline) - above (Day 85)	0	0	0	
Eosinophils Above (baseline) - above (Day 85)	3	0	0	
Hemoglobin Above (baseline) - above (Day 85)	4	3	2	

Lymphocytes Above (baseline) - above (Day 85)	0	0	0	
Monocytes Above (baseline) - above (Day 85)	0	1	0	
Neutrophils Above (baseline) - above (Day 85)	0	1	0	
Platelets Above (baseline) - above (Day 85)	3	4	2	
WBC Above (baseline) - above (Day 85)	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 197

End point title	Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test results at Day 197 ^[71] ^[72]
-----------------	--

End point description:

Assessed hepatic laboratory parameters included ALT and AST, and renal laboratory parameters included creatinine and urea/blood urea nitrogen. Hematological laboratory parameters included basophils, eosinophils, hemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBCs). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 197 (28 days after the third study intervention administration) compared to Baseline (Day 169)

Notes:

[71] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. No statistical hypothesis test was performed.

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42	38	14	
Units: Participants				
ALT Below (baseline) - below (Day 197)	0	0	0	
AST Below (baseline) - below (Day 197)	0	0	0	
Creatinine Below (baseline) - below (Day 197)	4	4	1	
Urea Nitrogen Below (baseline) - below (Day 197)	4	3	3	
Basophils Below (baseline) - below (Day 197)	0	0	0	

Eosinophils Below (baseline) - below (Day 197)	0	0	0	
Hemoglobin Below (baseline) - below (Day 197)	1	0	0	
Lymphocytes Below (baseline) - below (Day 197)	0	0	0	
Monocytes Below (baseline) - below (Day 197)	0	0	0	
Neutrophils Below (baseline) - below (Day 197)	0	0	0	
Platelets Below (baseline) - below (Day 197)	1	0	0	
WBC Below (baseline) - below (Day 197)	0	0	0	
ALT Within (baseline) - below (Day 197)	0	0	0	
AST Within (baseline) - below (Day 197)	0	0	0	
Creatinine Within (baseline) - below (Day 197)	2	1	0	
Urea Nitrogen Within (baseline) - below (Day 197)	9	5	1	
Basophils Within (baseline) - below (Day 197)	0	0	0	
Eosinophils Within (baseline) - below (Day 197)	0	0	0	
Hemoglobin Within (baseline) - below (Day 197)	0	0	0	
Lymphocytes Within (baseline) - below (Day 197)	0	0	0	
Monocytes Within (baseline) - below (Day 197)	0	0	0	
Neutrophils Within (baseline) - below (Day 197)	0	1	0	
Platelets Within (baseline) - below (Day 197)	0	0	0	
WBC Within (baseline) - below (Day 197)	0	0	0	
ALT Above (baseline) - below (Day 197)	0	0	0	
AST Above (baseline) - below (Day 197)	0	0	0	
Creatinine Above (baseline) - below (Day 197)	0	0	0	
Urea Nitrogen Above (baseline) - below (Day 197)	0	0	0	
Basophils Above (baseline) - below (Day 197)	0	0	0	
Eosinophils Above (baseline) - below (Day 197)	0	0	0	
Hemoglobin Above (baseline) - below (Day 197)	0	0	0	
Lymphocytes Above (baseline) - below (Day 197)	0	0	0	
Monocytes Above (baseline) - below (Day 197)	0	0	0	
Neutrophils Above (baseline) - below (Day 197)	0	0	0	
Platelets Above (baseline) - below (Day 197)	1	0	0	
WBC Above (baseline) - below (Day 197)	0	0	0	
ALT Below (baseline) - within (Day 197)	0	0	0	
AST Below (baseline) - within (Day 197)	0	0	0	

Creatinine Below (baseline) - within (Day 197)	0	0	0	
Urea Nitrogen Below (baseline) - within (Day 197)	8	2	1	
Basophils Below (baseline) - within (Day 197)	0	0	0	
Eosinophils Below (baseline) - within (Day 197)	0	0	0	
Hemoglobin Below (baseline) - within (Day 197)	1	0	0	
Lymphocytes Below (baseline) - within (Day 197)	0	0	0	
Monocytes Below (baseline) - within (Day 197)	0	0	0	
Neutrophils Below (baseline) - within (Day 197)	0	0	0	
Platelets Below (baseline) - within (Day 197)	0	1	0	
WBC Below (baseline) - within (Day 197)	0	0	0	
ALT Within (baseline) - within (Day 197)	38	30	13	
AST Within (baseline) - within (Day 197)	36	32	12	
Creatinine Within (baseline) - within (Day 197)	35	33	13	
Urea Nitrogen Within (baseline) - within (Day 197)	21	28	9	
Basophils Within (baseline) - within (Day 197)	42	38	14	
Eosinophils Within (baseline) - within (Day 197)	42	38	14	
Hemoglobin Within (baseline) - within (Day 197)	28	29	6	
Lymphocytes Within (baseline) - within (Day 197)	39	37	14	
Monocytes Within (baseline) - within (Day 197)	39	37	14	
Neutrophils Within (baseline) - within (Day 197)	42	33	14	
Platelets Within (baseline) - within (Day 197)	33	28	11	
WBC Within (baseline) - within (Day 197)	41	36	14	
ALT Above (baseline) - within (Day 197)	3	2	0	
AST Above (baseline) - within (Day 197)	2	2	0	
Creatinine Above (baseline) - within (Day 197)	0	0	0	
Urea Nitrogen Above (baseline) - within (Day 197)	0	0	0	
Basophils Above (baseline) - within (Day 197)	0	0	0	
Eosinophils Above (baseline) - within (Day 197)	0	0	0	
Hemoglobin Above (baseline) - within (Day 197)	6	2	3	
Lymphocytes Above (baseline) - within (Day 197)	1	1	0	
Monocytes Above (baseline) - within (Day 197)	1	1	0	
Neutrophils Above (baseline) - within (Day 197)	0	1	0	

Platelets Above (baseline) - within (Day 197)	4	5	0	
WBC Above (baseline) - within (Day 197)	0	1	0	
ALT Below (baseline) - above (Day 197)	0	0	0	
AST Below (baseline) - above (Day 197)	0	0	0	
Creatinine Below (baseline) - above (Day 197)	0	0	0	
Urea Nitrogen Below (baseline) - above (Day 197)	0	0	0	
Basophils Below (baseline) - above (Day 197)	0	0	0	
Eosinophils Below (baseline) - above (Day 197)	0	0	0	
Hemoglobin Below (baseline) - above (Day 197)	0	0	0	
Lymphocytes Below (baseline) - above (Day 197)	0	0	0	
Monocytes Below (baseline) - above (Day 197)	0	0	0	
Neutrophils Below (baseline) - above (Day 197)	0	0	0	
Platelets Below (baseline) - above (Day 197)	0	0	0	
WBC Below (baseline) - above (Day 197)	0	0	0	
ALT Within (baseline) - above (Day 197)	0	6	1	
AST Within (baseline) - above (Day 197)	1	2	1	
Creatinine Within (baseline) - above (Day 197)	1	0	0	
Urea Nitrogen Within (baseline) - above (Day 197)	0	0	0	
Basophils Within (baseline) - above (Day 197)	0	0	0	
Eosinophils Within (baseline) - above (Day 197)	0	0	0	
Hemoglobin Within (baseline) - above (Day 197)	1	1	1	
Lymphocytes Within (baseline) - above (Day 197)	1	0	0	
Monocytes Within (baseline) - above (Day 197)	1	0	0	
Neutrophils Within (baseline) - above (Day 197)	0	2	0	
Platelets Within (baseline) - above (Day 197)	2	0	1	
WBC Within (baseline) - above (Day 197)	1	0	0	
ALT Above (baseline) - above (Day 197)	1	0	0	
AST Above (baseline) - above (Day 197)	3	2	1	
Creatinine Above (baseline) - above (Day 197)	0	0	0	
Urea Nitrogen Above (baseline) - above (Day 197)	0	0	0	
Basophils Above (baseline) - above (Day 197)	0	0	0	
Eosinophils Above (baseline) - above (Day 197)	0	0	0	

Hemoglobin Above (baseline) - above (Day 197)	5	6	4	
Lymphocytes Above (baseline) - above (Day 197)	1	0	0	
Monocytes Above (baseline) - above (Day 197)	1	0	0	
Neutrophils Above (baseline) - above (Day 197)	0	1	0	
Platelets Above (baseline) - above (Day 197)	1	4	2	
WBC Above (baseline) - above (Day 197)	0	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Stage 1 and Stage 2: Number of participants with any SAEs

End point title	Stage 1 and Stage 2: Number of participants with any SAEs
End point description:	
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.	
End point type	Secondary
End point timeframe:	
From 28 days after the third study intervention administration (Day 197) up to study end (Day 337)	

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants	0	0	0	0

End point values	Stage 1: Placebo group	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	45	45	15
Units: Participants	0	0	1	1

Statistical analyses

Secondary: Stage 1 and Stage 2: Number of participants with any AEs/SAEs leading to withdrawal from the study

End point title	Stage 1 and Stage 2: Number of participants with any AEs/SAEs leading to withdrawal from the study
-----------------	--

End point description:

Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From 28 days after the third study intervention administration (Day 197) up to study end (Day 337)

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: Participants	0	0	0	0

End point values	Stage 1: Placebo group	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	45	45	15
Units: Participants	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Stage 1: Geometric mean concentrations (GMCs) of anti-serotype specific immunoglobulin G (IgG) in participants and between group ratios - Anti-Vi antigen (Ag) total IgG

End point title	Stage 1: Geometric mean concentrations (GMCs) of anti-serotype specific immunoglobulin G (IgG) in participants and between group ratios - Anti-Vi antigen (Ag) total IgG ^[73]
-----------------	--

End point description:

Anti-Vi antigen (Ag) total IgG GMCs were assessed. Blood samples were collected at specified timepoint for each component as measured by Enzyme-Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) for antibody concentrations was ≥ 2.2 microgram per milliliter ($\mu\text{g/mL}$). In case the measured antibody concentration fell below $2.2 \mu\text{g/mL}$, a value of half the LLOQ value was imputed. The analysis was performed on the Per Protocol Set (PPS), that included all eligible participants who received all doses as per protocol, had immunogenicity results post-dose, complied with dosing/blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without

prohibited concomitant medication/vaccination. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 1, 57, and 169 (before each study intervention administration) and at Days 29, 85, and 197 (28 days after each study intervention administration)

Notes:

[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: microgram per milliliter (µg/mL)				
geometric mean (confidence interval 95%)				
Anti-Vi Ag total IgG, Day 1	1.10 (1.10 to 1.10)	1.10 (1.10 to 1.10)	1.10 (1.10 to 1.10)	1.10 (1.10 to 1.10)
Anti-Vi Ag total IgG, Day 29	30.29 (13.50 to 67.95)	68.87 (1.73 to 2741.00)	43.55 (18.51 to 102.49)	66.48 (37.31 to 118.46)
Anti-Vi Ag total IgG, Day 57	23.28 (16.49 to 32.89)	53.95 (2.37 to 1226.99)	25.99 (9.86 to 68.50)	51.01 (27.55 to 94.46)
Anti-Vi Ag total IgG, Day 85	30.52 (14.75 to 63.13)	51.71 (3.42 to 781.48)	34.02 (16.67 to 69.44)	51.65 (31.18 to 85.55)
Anti-Vi Ag total IgG, Day 169	13.61 (4.28 to 43.23)	14.11 (0.22 to 10265.73)	15.76 (8.14 to 30.48)	20.69 (12.68 to 33.76)
Anti-Vi Ag total IgG, Day 197	20.19 (1.48 to 275.08)	17.43 (0.01 to 26224.47)	31.84 (16.24 to 62.43)	35.24 (23.65 to 52.49)

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: microgram per milliliter (µg/mL)				
geometric mean (confidence interval 95%)				
Anti-Vi Ag total IgG, Day 1	1.10 (1.10 to 1.10)			
Anti-Vi Ag total IgG, Day 29	1.10 (1.10 to 1.10)			
Anti-Vi Ag total IgG, Day 57	1.10 (1.10 to 1.10)			
Anti-Vi Ag total IgG, Day 85	1.10 (1.10 to 1.10)			
Anti-Vi Ag total IgG, Day 169	1.10 (1.10 to 1.10)			
Anti-Vi Ag total IgG, Day 197	1.10 (1.10 to 1.10)			

Statistical analyses

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 29	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[74]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	3.43

Notes:

[74] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 29	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[75]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.25
upper limit	1.7

Notes:

[75] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 197	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[76]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.44
upper limit	1.84

Notes:

[76] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 85	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[77]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	1.43

Notes:

[77] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 169	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[78]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.18
upper limit	5.12

Notes:

[78] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 169	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[79]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	1.6

Notes:

[79] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 197	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[80]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.23
upper limit	5.79

Notes:

[80] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 57	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[81]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	1.37

Notes:

[81] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 57	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[82]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	2.94

Notes:

[82] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-Vi Ag IgG, Day 85	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[83]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	2.65

Notes:

[83] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Secondary: Stage 1: GMCs of anti-serotype specific IgG in participants and between group ratios - Anti-S. Typhimurium OAg total IgG and Anti S. Enteritidis OAg total IgG

End point title	Stage 1: GMCs of anti-serotype specific IgG in participants and between group ratios - Anti-S. Typhimurium OAg total IgG and Anti S. Enteritidis OAg total IgG ^[84]
-----------------	--

End point description:

Anti-S. Typhimurium OAg total IgG, Anti S. Enteritidis OAg total IgG GMCs were assessed. Blood samples were collected at specified timepoint for each component as measured by Enzyme-Linked Immunosorbent Assay (ELISA).

The analysis was performed on the Per Protocol Set (PPS), that included all eligible participants who

received all doses as per protocol, had immunogenicity results post-dose, complied with dosing/blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 1, 57, and 169 (before each study intervention administration) and at Days 29, 85, and 197 (28 days after each study intervention administration)

Notes:

[84] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	16	16
Units: ELISA units per milliliter (EU/mL)				
geometric mean (confidence interval 95%)				
Anti-S.Typhimurium OAg IgG, Day 1	20.25 (3.23 to 126.95)	49.45 (0.68 to 3599.82)	94.10 (34.63 to 255.69)	124.02 (54.83 to 280.53)
Anti-S.Typhimurium OAg IgG, Day 29	494.50 (80.16 to 3050.49)	169.25 (4.35 to 6586.95)	1426.07 (777.69 to 2615.85)	1505.55 (815.65 to 2778.99)
Anti-S.Typhimurium OAg IgG, Day 57	423.33 (81.46 to 2200.08)	139.78 (5.42 to 3604.75)	1075.57 (466.12 to 2481.85)	1203.79 (589.73 to 2457.26)
Anti-S.Typhimurium OAg IgG, Day 85	410.29 (87.67 to 1920.18)	243.42 (3.18 to 18606.83)	1129.27 (497.20 to 2564.86)	1478.01 (804.57 to 2715.11)
Anti-S.Typhimurium OAg IgG, Day 169	272.19 (43.10 to 1718.88)	109.20 (0.00 to 10400000000000)	703.74 (296.98 to 1667.63)	951.71 (498.59 to 1816.63)
Anti-S.Typhimurium OAg IgG, Day 197	249.07 (21.83 to 2842.34)	163.07 (0.00 to 11900000000000)	1005.05 (445.54 to 2267.20)	1176.88 (719.47 to 1925.10)
Anti-S.Enteritidis OAg IgG, Day 1	67.85 (6.04 to 761.69)	42.77 (0.32 to 5784.66)	125.64 (47.39 to 333.09)	115.74 (46.32 to 289.22)
Anti-S.Enteritidis OAg IgG, Day 29	920.64 (104.11 to 8141.15)	169.46 (0.32 to 90734.61)	1648.46 (1023.81 to 2654.22)	1387.16 (587.94 to 3272.77)
Anti-S.Enteritidis OAg IgG, Day 57	832.83 (110.24 to 6291.99)	141.59 (0.42 to 47560.41)	1454.26 (801.81 to 2637.64)	1076.32 (400.41 to 2893.21)
Anti-S.Enteritidis OAg IgG, Day 85	882.68 (132.51 to 5879.62)	209.03 (0.88 to 49901.51)	1436.56 (779.81 to 2646.42)	1267.65 (511.67 to 3140.56)
Anti-S.Enteritidis OAg IgG, Day 169	557.81 (78.28 to 3975.01)	42.14 (0.01 to 162000)	903.37 (487.13 to 1675.30)	729.86 (255.41 to 2085.64)
Anti-S.Enteritidis OAg IgG, Day 197	451.36 (22.54 to 9036.65)	81.17 (0.87 to 7578.12)	1168.56 (642.31 to 2125.99)	855.62 (356.65 to 2052.67)

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: ELISA units per milliliter (EU/mL)				
geometric mean (confidence interval 95%)				
Anti-S.Typhimurium OAg IgG, Day 1	52.23 (19.31 to 141.31)			
Anti-S.Typhimurium OAg IgG, Day 29	52.86 (19.93 to 140.20)			
Anti-S.Typhimurium OAg IgG, Day 57	58.38 (16.45 to 207.16)			
Anti-S.Typhimurium OAg IgG, Day 85	68.07 (17.22 to 269.09)			
Anti-S.Typhimurium OAg IgG, Day 169	75.80 (21.92 to 262.14)			
Anti-S.Typhimurium OAg IgG, Day 197	73.43 (21.98 to 245.25)			
Anti-S.Enteritidis OAg IgG, Day 1	57.08 (21.97 to 148.25)			
Anti-S.Enteritidis OAg IgG, Day 29	56.62 (21.49 to 149.13)			
Anti-S.Enteritidis OAg IgG, Day 57	65.49 (18.13 to 236.58)			
Anti-S.Enteritidis OAg IgG, Day 85	79.79 (18.55 to 343.09)			
Anti-S.Enteritidis OAg IgG, Day 169	75.96 (20.72 to 278.48)			
Anti-S.Enteritidis OAg IgG, Day 197	73.74 (20.17 to 269.56)			

Statistical analyses

Statistical analysis title	Between-group analysis
Statistical analysis description:	
Anti-S.Typhimurium OAg IgG Day 29	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[85]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	2.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	17.8

Notes:

[85] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 29	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[86]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	2.19

Notes:

[86] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 57	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[87]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	3.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	21.45

Notes:

[87] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 57	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[88]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.33
upper limit	2.45

Notes:

[88] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 85	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[89]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.26
upper limit	10.96

Notes:

[89] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 85	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[90]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	2

Notes:

[90] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 169	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[91]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	2.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.24
upper limit	26.3

Notes:

[91] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 169	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[92]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.26
upper limit	2.11

Notes:

[92] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 197	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group

Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[93]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	12.41

Notes:

[93] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 197	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[94]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	2.15

Notes:

[94] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 85	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[95]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	4.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	37.19

Notes:

[95] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 57	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[96]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	4.45

Notes:

[96] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 57	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[97]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	5.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	59.45

Notes:

[97] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 29	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group

Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[98]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	3.26

Notes:

[98] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 29	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[99]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	5.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	48.17

Notes:

[99] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 169	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[100]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	13.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.02
upper limit	172.55

Notes:

[100] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 85	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[101]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	3.48

Notes:

[101] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 169	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[102]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	3.88

Notes:

[102] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 197	
Comparison groups	Stage 1: iNTS-TCV low dose group v Stage 1: iNTS-GMMA + TCV low dose group

Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	other ^[103]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	5.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	58.61

Notes:

[103] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 197	
Comparison groups	Stage 1: iNTS-TCV full dose group v Stage 1: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	other ^[104]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	3.86

Notes:

[104] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Secondary: Stage 1: Geometric mean ratios (GMRs) for anti-serotype specific immunoglobulin G (IgG) concentrations

End point title	Stage 1: Geometric mean ratios (GMRs) for anti-serotype specific immunoglobulin G (IgG) concentrations ^[105]
End point description: Anti-Vi antigen (Ag) total IgG, Anti-S. Typhimurium OAg total IgG, AntiS. Enteritidis OAg total IgG within-participant GMRs were assessed. Blood samples were collected at specified timepoint for each component as measured by ELISA. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.	
End point type	Secondary

End point timeframe:

At 28 days after each study intervention administration compared to each study intervention administration baseline (Day 29 versus Day 1, Day 85 versus Day 57 and Day 197 versus Day 169)

Notes:

[105] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	16	16
Units: Ratio				
geometric mean (confidence interval 95%)				
Anti-Vi Ag total IgG, Day 29	27.53 (12.27 to 61.77)	62.61 (1.57 to 2491.81)	39.60 (16.83 to 93.18)	60.44 (33.92 to 107.69)
Anti-Vi Ag total IgG, Day 85	1.31 (0.80 to 2.14)	0.96 (0.47 to 1.96)	1.31 (0.87 to 1.97)	1.01 (0.78 to 1.31)
Anti-Vi Ag total IgG, Day 197	1.96 (0.49 to 7.78)	1.24 (0.60 to 2.55)	1.99 (1.38 to 2.89)	1.70 (1.38 to 2.10)
Anti-S.Typhimurium OAg IgG. Day 29	24.42 (11.30 to 52.75)	3.42 (0.48 to 24.20)	15.15 (5.57 to 41.26)	12.14 (6.83 to 21.58)
Anti-S.Typhimurium OAg IgG. Day 85	0.97 (0.63 to 1.50)	1.74 (0.44 to 6.87)	1.05 (0.86 to 1.28)	1.23 (0.89 to 1.69)
Anti-S.Typhimurium OAg IgG. Day 197	1.47 (0.80 to 2.71)	1.49 (1.14 to 1.95)	1.20 (1.01 to 1.44)	1.24 (0.93 to 1.65)
Anti-S.Enteritidis OAg IgG Day 29	13.57 (3.76 to 48.93)	3.96 (0.67 to 23.52)	13.12 (5.41 to 31.80)	11.98 (6.57 to 21.86)
Anti-S.Enteritidis OAg IgG Day 85	1.06 (0.90 to 1.24)	1.48 (0.59 to 3.67)	0.99 (0.86 to 1.14)	1.18 (0.82 to 1.69)
Anti-S.Enteritidis OAg IgG Day 197	1.29 (0.68 to 2.45)	1.93 (0.05 to 79.54)	1.15 (1.03 to 1.28)	1.17 (0.92 to 1.49)

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Ratio				
geometric mean (confidence interval 95%)				
Anti-Vi Ag total IgG, Day 29	1.00 (1.00 to 1.00)			
Anti-Vi Ag total IgG, Day 85	1.00 (1.00 to 1.00)			
Anti-Vi Ag total IgG, Day 197	1.00 (1.00 to 1.00)			
Anti-S.Typhimurium OAg IgG. Day 29	1.01 (0.94 to 1.09)			
Anti-S.Typhimurium OAg IgG. Day 85	1.17 (0.97 to 1.40)			
Anti-S.Typhimurium OAg IgG. Day 197	0.97 (0.90 to 1.04)			
Anti-S.Enteritidis OAg IgG Day 29	0.99 (0.93 to 1.06)			
Anti-S.Enteritidis OAg IgG Day 85	1.22 (0.97 to 1.53)			
Anti-S.Enteritidis OAg IgG Day 197	0.97 (0.95 to 0.99)			

Statistical analyses

Secondary: Stage 1: Number of participants achieving at least a 4 fold rise in anti serotype specific immunoglobulin G (IgG) antibody concentration for each antigen (Ag)

End point title	Stage 1: Number of participants achieving at least a 4 fold rise in anti serotype specific immunoglobulin G (IgG) antibody concentration for each antigen (Ag) ^[106]
-----------------	---

End point description:

Anti-Vi Ag total IgG, Anti-S. Typhimurium OAg total IgG, Anti-S. Enteritidis OAg total IgG antibody concentrations were assessed. Blood samples were collected at specified timepoint for each component as measured by ELISA. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 29, 85, and 197 (28 days after each study intervention administration) compared to Day 1 (first study intervention administration)

Notes:

[106] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	16	16
Units: Participants				
Anti-Vi Ag IgG, Day 29	4	3	13	16
Anti-Vi Ag IgG, Day 85	4	3	10	14
Anti-Vi Ag IgG, Day 197	2	2	10	14
Anti-S.Typhimurium OAg IgG, Day 29	4	1	13	15
Anti-S.Typhimurium OAg IgG, Day 85	4	2	8	14
Anti-S.Typhimurium OAg IgG, Day 197	3	1	6	10
Anti-S.Enteritidis OAg IgG, Day 29	4	1	11	12
Anti-S.Enteritidis OAg IgG, Day 85	4	2	7	11
Anti-S.Enteritidis OAg IgG, Day 197	3	1	4	10

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Anti-Vi Ag IgG, Day 29	0			
Anti-Vi Ag IgG, Day 85	0			
Anti-Vi Ag IgG, Day 197	0			
Anti-S.Typhimurium OAg IgG, Day 29	0			
Anti-S.Typhimurium OAg IgG, Day 85	1			
Anti-S.Typhimurium OAg IgG, Day 197	1			
Anti-S.Enteritidis OAg IgG, Day 29	0			
Anti-S.Enteritidis OAg IgG, Day 85	1			

Anti-S.Enteritidis OAg IgG, Day 197	1			
-------------------------------------	---	--	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Stage 1: Number of participants with Anti-Vi Ag IgG antibody concentrations greater than or equal to (\geq) 4.3 micrograms per milliliter ($\mu\text{g/mL}$)

End point title	Stage 1: Number of participants with Anti-Vi Ag IgG antibody concentrations greater than or equal to (\geq) 4.3 micrograms per milliliter ($\mu\text{g/mL}$) ^[107]
-----------------	---

End point description:

Blood samples were collected at specified timepoint for each component as measured by ELISA. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 1, 57 and 169 (before each study intervention administration) and at Days 29, 85 and 197 (28 days after each study intervention administration)

Notes:

[107] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group	Stage 1: iNTS-GMMA + TCV full dose group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	3	16	16
Units: Participants				
Day 1 (pre-Dose 1)	0	0	0	0
Day 29	4	3	14	16
Day 57 (pre-Dose 2)	4	3	9	14
Day 85	4	3	12	14
Day 169 (pre-Dose 3)	4	2	11	14
Day 197	3	2	11	14

End point values	Stage 1: Placebo group			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Day 1 (pre-Dose 1)	0			
Day 29	0			
Day 57 (pre-Dose 2)	0			
Day 85	0			

Day 169 (pre-Dose 3)	0			
Day 197	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Stage 2: GMCs of anti-serotype specific IgG in participants and between group ratios - Anti-Vi Ag total IgG

End point title	Stage 2: GMCs of anti-serotype specific IgG in participants and between group ratios - Anti-Vi Ag total IgG ^[108]
-----------------	--

End point description:

Anti-Vi Ag total IgG GMCs and between group ratios were assessed. Blood samples were collected at specified timepoint for each component as measured by ELISA. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 1, 57, and 169 (before each study intervention administration) and at Days 29, 85, and 197 (28 days after each study intervention administration)

Notes:

[108] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	15	
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-Vi Ag total IgG, Day 1	1.43 (1.20 to 1.70)	1.38 (1.13 to 1.69)	1.56 (1.11 to 2.19)	
Anti-Vi Ag total IgG, Day 29	148.98 (103.31 to 214.83)	161.68 (107.38 to 243.46)	1.55 (1.04 to 2.33)	
Anti-Vi Ag total IgG, Day 57	96.93 (67.00 to 140.23)	104.38 (69.77 to 156.16)	1.60 (1.01 to 2.53)	
Anti-Vi Ag total IgG, Day 85	96.94 (72.03 to 130.48)	101.92 (72.02 to 144.24)	1.65 (1.08 to 2.52)	
Anti-Vi Ag total IgG, Day 169	41.83 (29.43 to 59.46)	53.65 (34.97 to 82.32)	1.88 (1.18 to 2.99)	
Anti-Vi Ag total IgG, Day 197	65.43 (51.01 to 83.92)	69.82 (50.09 to 97.30)	18.60 (8.28 to 41.76)	

Statistical analyses

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-S.Typhi Vi Ag IgG Day 29	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[109]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.58

Notes:

[109] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-S.Typhi Vi Ag IgG Day 57	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[110]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.59

Notes:

[110] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Antigen Anti-S.Typhi Vi Ag IgG Day 197	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[111]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.94

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.4

Notes:

[111] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
-----------------------------------	------------------------

Statistical analysis description:

Antigen Anti-S.Typhi Vi Ag IgG Day 169

Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[112]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	1.34

Notes:

[112] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
-----------------------------------	------------------------

Statistical analysis description:

Antigen Anti-S.Typhi Vi Ag IgG Day 85

Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[113]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	1.49

Notes:

[113] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Secondary: Stage 2: GMCs of anti-serotype specific IgG in participants and between group ratios - Anti-S. Typhimurium OAg total IgG and AntiS. Enteritidis OAg total IgG

End point title	Stage 2: GMCs of anti-serotype specific IgG in participants and between group ratios - Anti-S. Typhimurium OAg total IgG and
-----------------	--

End point description:

Anti-S. Typhimurium OAg total IgG and Anti S. Enteritidis OAg total IgG GMCs and between group ratios were assessed. Blood samples were collected at specified timepoint for each component as measured by ELISA. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type

Secondary

End point timeframe:

At Days 1, 57, and 169 (before each study intervention administration) and at Days 29, 85, and 197 (28 days after each study intervention administration)

Notes:

[114] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	15	
Units: EU/mL				
geometric mean (confidence interval 95%)				
Anti-S.Typhimurium OAg IgG, Day 1	246.02 (167.63 to 361.07)	490.94 (378.78 to 636.31)	392.99 (273.90 to 563.87)	
Anti-S.Typhimurium OAg IgG, Day 29	1591.68 (1117.07 to 2267.94)	2585.81 (2024.74 to 3302.35)	446.22 (290.49 to 685.45)	
Anti-S.Typhimurium OAg IgG, Day 57	1159.50 (806.72 to 1666.56)	1794.69 (1419.63 to 2268.85)	483.46 (329.52 to 709.32)	
Anti-S.Typhimurium OAg IgG, Day 85	1102.67 (771.64 to 1575.70)	1765.79 (1395.81 to 2233.85)	545.05 (355.58 to 835.46)	
Anti-S.Typhimurium OAg IgG, Day 169	870.80 (552.07 to 1373.57)	1248.95 (979.10 to 1593.18)	565.73 (349.09 to 916.82)	
Anti-S.Typhimurium OAg IgG, Day 197	992.82 (645.92 to 1526.03)	1748.80 (1359.79 to 2249.09)	542.87 (340.01 to 866.75)	
Anti-S.Enteritidis OAg IgG, Day 1	363.08 (228.49 to 576.96)	376.17 (270.58 to 522.95)	394.19 (193.54 to 802.88)	
Anti-S.Enteritidis OAg IgG, Day 29	1884.94 (1272.38 to 2792.41)	2295.38 (1642.33 to 3208.10)	457.08 (209.54 to 997.03)	
Anti-S.Enteritidis OAg IgG, Day 57	1527.50 (1030.99 to 2263.13)	1581.75 (1153.18 to 2169.60)	470.88 (214.12 to 1035.51)	
Anti-S.Enteritidis OAg IgG, Day 85	1604.28 (1109.24 to 2320.23)	1555.91 (1134.43 to 2133.97)	456.04 (215.01 to 967.26)	
Anti-S.Enteritidis OAg IgG, Day 169	946.93 (646.79 to 1386.34)	1015.74 (727.61 to 1417.95)	408.69 (190.40 to 877.23)	
Anti-S.Enteritidis OAg IgG, Day 197	1093.84 (757.63 to 1579.27)	1327.68 (972.03 to 1813.45)	423.08 (213.16 to 839.75)	

Statistical analyses

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 29	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[115]
Method	Mixed models analysis
Parameter estimate	Adjusted GMR
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.32

Notes:

[115] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 85	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[116]
Method	Mixed models analysis
Parameter estimate	Adjusted GMR
Point estimate	1.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.41

Notes:

[116] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 169	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[117]
Method	Mixed models analysis
Parameter estimate	Adjusted GMR
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.77

Notes:

[117] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 57	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[118]
Method	Mixed models analysis
Parameter estimate	Adjusted GMR
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.37

Notes:

[118] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Typhimurium OAg IgG Day 197	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[119]
Method	Mixed models analysis
Parameter estimate	Adjusted GMR
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.44

Notes:

[119] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 29	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[120]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.37

Notes:

[120] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 57	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[121]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.59

Notes:

[121] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 85	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[122]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	1.67

Notes:

[122] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 169	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[123]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.54

Notes:

[123] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Statistical analysis title	Between-group analysis
Statistical analysis description: Anti-S.Enteritidis OAg IgG Day 197	
Comparison groups	Stage 2: iNTS-TCV full dose group v Stage 2: iNTS-GMMA + TCV full dose group
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other ^[124]
Method	ANOVA
Parameter estimate	Unadjusted GMR
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.33

Notes:

[124] - The statistical analyses performed for the study objectives were descriptive. No success criteria were defined for the statistical analyses conducted in this study.

Secondary: Stage 2: GMRs for anti-serotype specific immunoglobulin G (IgG) concentrations

End point title	Stage 2: GMRs for anti-serotype specific immunoglobulin G (IgG) concentrations ^[125]
-----------------	---

End point description:

Anti-Vi antigen (Ag) total IgG, Anti-S. Typhimurium OAg total IgG, AntiS. Enteritidis OAg total IgG within-participant GMRs were assessed. Blood samples were collected at specified timepoint for each component as measured by ELISA. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At 28 days after each study intervention administration compared to each study intervention administration baseline (Day 29 versus Day 1, Day 85 versus Day 57 and Day 197 versus Day 169)

Notes:

[125] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 1 of the baseline period. Stage 2 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	15	
Units: Ratio				
geometric mean (confidence interval 95%)				
Anti-Vi Ag total IgG, Day 29	104.51 (77.39 to 141.12)	116.84 (79.82 to 171.01)	1.00 (0.74 to 1.34)	
Anti-Vi Ag total IgG, Day 85	1.05 (0.92 to 1.20)	0.91 (0.83 to 1.00)	1.03 (0.92 to 1.16)	
Anti-Vi Ag total IgG, Day 197	1.56 (1.30 to 1.88)	1.37 (1.10 to 1.69)	9.89 (5.14 to 19.04)	
Anti-S.Typhimurium OAg IgG. Day 29	6.47 (4.97 to 8.42)	5.27 (4.12 to 6.73)	1.14 (0.83 to 1.55)	
Anti-S.Typhimurium OAg IgG. Day 85	1.00 (0.92 to 1.10)	0.97 (0.89 to 1.06)	1.13 (0.89 to 1.42)	
Anti-S.Typhimurium OAg IgG. Day 197	1.14 (1.04 to 1.25)	1.41 (1.18 to 1.70)	0.96 (0.81 to 1.14)	
Anti-S.Enteritidis OAg IgG Day 29	5.19 (3.44 to 7.83)	6.10 (4.47 to 8.33)	1.16 (0.82 to 1.65)	
Anti-S.Enteritidis OAg IgG Day 85	1.04 (0.94 to 1.15)	0.99 (0.90 to 1.10)	0.97 (0.83 to 1.13)	
Anti-S.Enteritidis OAg IgG Day 197	1.16 (1.00 to 1.34)	1.34 (1.11 to 1.62)	1.04 (0.86 to 1.25)	

Statistical analyses

No statistical analyses for this end point

Secondary: Stage 2: Number of participants achieving at least a 4 fold rise in anti serotype specific immunoglobulin G (IgG) antibody concentration for each antigen (Ag)

End point title	Stage 2: Number of participants achieving at least a 4 fold rise in anti serotype specific immunoglobulin G (IgG) antibody concentration for each antigen (Ag) ^[126]
-----------------	---

End point description:

Anti-Vi Ag total IgG, Anti-S. Typhimurium OAg total IgG, Anti-S. Enteritidis OAg total IgG antibody concentrations were assessed. Blood samples were collected at specified timepoint for each component as measured by ELISA. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 29, 85, and 197 (28 days after each study intervention administration) compared to Day 1 (first study intervention administration baseline)

Notes:

[126] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	15	
Units: Participants				
Anti-Vi Ag IgG, Day 29	44	43	0	
Anti-Vi Ag IgG, Day 85	44	42	1	
Anti-Vi Ag IgG, Day 197	41	37	9	
Anti-S.Typhimurium OAg IgG, Day 29	33	27	1	
Anti-S.Typhimurium OAg IgG, Day 85	22	16	1	
Anti-S.Typhimurium OAg IgG, 197	23	16	1	
Anti-S.Enteritidis OAg IgG, 29	23	27	1	
Anti-S.Enteritidis OAg IgG, Day 85	21	18	2	
Anti-S.Enteritidis OAg IgG, Day 197	17	16	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Stage 2: Number of participants with Anti-Vi Ag IgG antibody concentrations $\geq 4.3 \mu\text{g/mL}$

End point title	Stage 2: Number of participants with Anti-Vi Ag IgG antibody concentrations $\geq 4.3 \mu\text{g/mL}$ ^[127]
-----------------	--

End point description:

Blood samples were collected at specified timepoint for each component as measured by ELISA. The analysis was performed on the PPS. Only participants with data available at the mentioned timepoints were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 1, 57 and 169 (before each study intervention administration) and at Days 29, 85 and 197 (28 days after each study intervention administration)

Notes:

[127] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting data for only Stage 2 of the baseline period. Stage 1 data is presented separately.

End point values	Stage 2: iNTS-TCV full dose group	Stage 2: iNTS-GMMA + TCV full dose group	Stage 2: Control group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	15	
Units: Participants				
Day 1	4	3	3	
Day 29	45	44	3	
Day 57	45	44	3	
Day 85	44	43	3	
Day 169	41	37	3	
Day 197	41	37	12	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

SAEs: From Day 1 to Day 337 (end of study), Solicited AEs: From Day 1 to Day 7, Day 57 to Day 63 and Day 169 to Day 175, and Unsolicited AEs: From Day 1 to Day 28, Day 57 to Day 84 and Day 169 to Day 196.

Adverse event reporting additional description:

SAEs, solicited AEs and unsolicited AEs were reported for the Exposed set.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	v27.1
--------------------	-------

Reporting groups

Reporting group title	Stage 1: iNTS-TCV low dose group
-----------------------	----------------------------------

Reporting group description:

European participants were randomized to receive 3 doses of Invasive nontyphoidal Salmonella (iNTS)-Typhoid conjugate vaccine (TCV) low dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Reporting group title	Stage 1: iNTS-GMMA + TCV low dose group
-----------------------	---

Reporting group description:

European participants were randomized to receive 3 doses of iNTS-Generalized modules for membrane antigens (GMMA) low dose vaccine and 3 doses of TCV low dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Reporting group title	Stage 1: iNTS-TCV full dose group
-----------------------	-----------------------------------

Reporting group description:

European participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Reporting group title	Stage 1: iNTS-GMMA + TCV full dose group
-----------------------	--

Reporting group description:

European participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Reporting group title	Stage 2: iNTS-TCV full dose group
-----------------------	-----------------------------------

Reporting group description:

African participants were randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Reporting group title	Stage 1: Placebo group
-----------------------	------------------------

Reporting group description:

European participants were randomized to receive 3 doses of Placebo and 3 doses of saline solution intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Reporting group title	Stage 2: Control group
-----------------------	------------------------

Reporting group description:

African participants were randomized to receive MENVEO as comparator and 1 dose of saline on Day 1, BOOSTRIX as comparator and 1 dose of saline on Day 57 and TYPHIM VI as comparator and 1 dose of saline on Day 169.

Reporting group title	Stage 2: iNTS-GMMA + TCV full dose group
-----------------------	--

Reporting group description:

African participants were randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose intramuscularly, in different arms, on Day 1, Day 57 and Day 169.

Serious adverse events	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Malaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Stage 1: iNTS- GMMA + TCV full dose group	Stage 2: iNTS-TCV full dose group	Stage 1: Placebo group
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Nervous system disorders			
Epilepsy			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			

subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Malaria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Stage 2: Control group	Stage 2: iNTS-GMMA + TCV full dose group	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 15 (6.67%)	2 / 45 (4.44%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Malaria			
subjects affected / exposed	1 / 15 (6.67%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Stage 1: iNTS-TCV low dose group	Stage 1: iNTS-GMMA + TCV low dose group	Stage 1: iNTS-TCV full dose group
Total subjects affected by non-serious adverse events subjects affected / exposed	4 / 4 (100.00%)	4 / 4 (100.00%)	16 / 16 (100.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Administration site erythema			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	8 / 16 (50.00%)
occurrences (all)	1	0	13
Administration site pain			
subjects affected / exposed	4 / 4 (100.00%)	4 / 4 (100.00%)	16 / 16 (100.00%)
occurrences (all)	15	13	44
Administration site pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Administration site swelling			
subjects affected / exposed	1 / 4 (25.00%)	1 / 4 (25.00%)	6 / 16 (37.50%)
occurrences (all)	1	1	8
Administration site warmth			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	2
Fatigue			
subjects affected / exposed	2 / 4 (50.00%)	4 / 4 (100.00%)	10 / 16 (62.50%)
occurrences (all)	4	5	18
Feeling hot			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injection site hyperaesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injection site pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injection site induration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injection site rash			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Injection site warmth			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	2
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 4 (50.00%)	3 / 16 (18.75%)
occurrences (all)	0	2	4
Thirst			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pain			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypothermia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vaccination site urticaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Penile pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Dysphonia			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Investigations			
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	3 / 16 (18.75%) 3
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	2 / 16 (12.50%) 2
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	1 / 16 (6.25%) 1
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	2 / 16 (12.50%) 2
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	1 / 16 (6.25%) 1
Heart rate decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Blood creatinine decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Injury, poisoning and procedural complications			
Procedural pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Limb injury			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cataract traumatic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Radius fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Soft tissue injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Bradycardia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 4 (75.00%)	3 / 4 (75.00%)	8 / 16 (50.00%)
occurrences (all)	4	4	15
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Loss of consciousness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Blood and lymphatic system disorders Neutrophilia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Monocytosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Lymphopenia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Ear and labyrinth disorders Cerumen impaction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	0 / 16 (0.00%) 0
Eye disorders Chalazion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 4 (0.00%) 0	1 / 16 (6.25%) 1
Photophobia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	1 / 16 (6.25%)
occurrences (all)	0	2	1
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal sounds abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hyperhidrosis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pigmentation disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Urethral discharge			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 4 (25.00%)	2 / 4 (50.00%)	3 / 16 (18.75%)
occurrences (all)	1	2	5
Pain in jaw			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			

subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	4 / 4 (100.00%)	3 / 4 (75.00%)	9 / 16 (56.25%)
occurrences (all)	7	3	15
Musculoskeletal stiffness			
subjects affected / exposed	2 / 4 (50.00%)	1 / 4 (25.00%)	2 / 16 (12.50%)
occurrences (all)	2	1	2
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Sacral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Muscle swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Epididymitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	2 / 16 (12.50%)
occurrences (all)	2	0	2
Onychomycosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	3 / 16 (18.75%)
occurrences (all)	1	0	3
Sinusitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	2 / 16 (12.50%)
occurrences (all)	2	0	2
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Acarodermatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Body tinea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Influenza			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pelvic inflammatory disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Tinea versicolour			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Stage 1: iNTS-GMMA + TCV full dose group	Stage 2: iNTS-TCV full dose group	Stage 1: Placebo group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 16 (100.00%)	43 / 45 (95.56%)	9 / 10 (90.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Hypotension subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
General disorders and administration site conditions			
Administration site erythema subjects affected / exposed occurrences (all)	7 / 16 (43.75%) 12	6 / 45 (13.33%) 7	0 / 10 (0.00%) 0
Administration site pain subjects affected / exposed occurrences (all)	16 / 16 (100.00%) 54	40 / 45 (88.89%) 145	8 / 10 (80.00%) 19
Administration site pruritus subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Administration site swelling subjects affected / exposed occurrences (all)	3 / 16 (18.75%) 5	13 / 45 (28.89%) 23	0 / 10 (0.00%) 0
Administration site warmth subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Chills subjects affected / exposed occurrences (all)	2 / 16 (12.50%) 2	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	12 / 16 (75.00%) 24	31 / 45 (68.89%) 59	3 / 10 (30.00%) 3
Feeling hot subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	3 / 16 (18.75%) 3	0 / 45 (0.00%) 0	1 / 10 (10.00%) 1
Injection site hyperaesthesia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Injection site pruritus			

subjects affected / exposed	3 / 16 (18.75%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	4	0	0
Injection site induration			
subjects affected / exposed	1 / 16 (6.25%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Injection site rash			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Injection site warmth			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	2 / 16 (12.50%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	3	0	0
Pyrexia			
subjects affected / exposed	2 / 16 (12.50%)	13 / 45 (28.89%)	1 / 10 (10.00%)
occurrences (all)	2	17	1
Thirst			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Vessel puncture site pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Hypothermia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Vaccination site urticaria			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Reproductive system and breast disorders			
Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Penile pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	2 / 45 (4.44%) 3	0 / 10 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Investigations			
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	2 / 10 (20.00%) 2
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 45 (4.44%) 2	0 / 10 (0.00%) 0

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 16 (12.50%) 2	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
White blood cell count increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Neutrophil count increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	1 / 45 (2.22%) 1	1 / 10 (10.00%) 1
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Heart rate decreased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Blood creatinine decreased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Injury, poisoning and procedural complications			
Procedural pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 45 (4.44%) 2	0 / 10 (0.00%) 0
Cataract traumatic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Animal bite subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Radius fracture			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Soft tissue injury subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Thermal burn subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Cardiac disorders Bradycardia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	11 / 16 (68.75%) 19	38 / 45 (84.44%) 70	4 / 10 (40.00%) 4
Paraesthesia subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	1 / 10 (10.00%) 1
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 45 (4.44%) 3	0 / 10 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	6 / 45 (13.33%) 7	0 / 10 (0.00%) 0
Loss of consciousness subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Syncope			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Blood and lymphatic system disorders			
Neutrophilia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Monocytosis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Cerumen impaction			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ear pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Chalazion			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ocular hyperaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	2 / 16 (12.50%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	2	1	0
Vomiting			
subjects affected / exposed	1 / 16 (6.25%)	2 / 45 (4.44%)	0 / 10 (0.00%)
occurrences (all)	1	4	0
Nausea			
subjects affected / exposed	1 / 16 (6.25%)	2 / 45 (4.44%)	1 / 10 (10.00%)
occurrences (all)	1	2	1
Abdominal pain			
subjects affected / exposed	0 / 16 (0.00%)	2 / 45 (4.44%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Toothache			
subjects affected / exposed	0 / 16 (0.00%)	2 / 45 (4.44%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal sounds abnormal			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pigmentation disorder			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Pruritus			
subjects affected / exposed	1 / 16 (6.25%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Rash erythematous			

subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urethral discharge			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 16 (25.00%)	21 / 45 (46.67%)	0 / 10 (0.00%)
occurrences (all)	7	36	0
Pain in jaw			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 16 (0.00%)	2 / 45 (4.44%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Myalgia			
subjects affected / exposed	11 / 16 (68.75%)	29 / 45 (64.44%)	1 / 10 (10.00%)
occurrences (all)	20	58	1
Musculoskeletal stiffness			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Back pain			

subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	1 / 10 (10.00%)
occurrences (all)	0	2	1
Sacral pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 16 (0.00%)	2 / 45 (4.44%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 16 (0.00%)	1 / 45 (2.22%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Muscle swelling			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	0 / 16 (0.00%)	3 / 45 (6.67%)	0 / 10 (0.00%)
occurrences (all)	0	3	0
Epididymitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	4 / 16 (25.00%)	0 / 45 (0.00%)	2 / 10 (20.00%)
occurrences (all)	4	0	2
Onychomycosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 45 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	8 / 45 (17.78%) 9	2 / 10 (20.00%) 2
Sinusitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	2 / 16 (12.50%) 2	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Acarodermatitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 2	0 / 10 (0.00%) 0
Body tinea subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	3 / 45 (6.67%) 4	0 / 10 (0.00%) 0
Pelvic inflammatory disease subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0

Tinea versicolour subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 45 (2.22%) 1	0 / 10 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 45 (0.00%) 0	0 / 10 (0.00%) 0

Non-serious adverse events	Stage 2: Control group	Stage 2: iNTS-GMMA + TCV full dose group	
Total subjects affected by non-serious adverse events subjects affected / exposed	15 / 15 (100.00%)	45 / 45 (100.00%)	
Vascular disorders			
Hot flush subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Hypertension subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Hypotension subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
General disorders and administration site conditions			
Administration site erythema subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	10 / 45 (22.22%) 19	
Administration site pain			

subjects affected / exposed	13 / 15 (86.67%)	45 / 45 (100.00%)
occurrences (all)	39	180
Administration site pruritus		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Administration site swelling		
subjects affected / exposed	2 / 15 (13.33%)	15 / 45 (33.33%)
occurrences (all)	4	40
Administration site warmth		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Chills		
subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Fatigue		
subjects affected / exposed	6 / 15 (40.00%)	30 / 45 (66.67%)
occurrences (all)	10	62
Feeling hot		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Influenza like illness		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Injection site hyperaesthesia		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Injection site pruritus		
subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Injection site induration		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Injection site rash		
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Injection site warmth		

subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Malaise			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Pyrexia			
subjects affected / exposed	0 / 15 (0.00%)	15 / 45 (33.33%)	
occurrences (all)	0	20	
Thirst			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vessel puncture site haematoma			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vessel puncture site pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Pain			
subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Hypothermia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Asthenia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vaccination site urticaria			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Peripheral swelling			
subjects affected / exposed	0 / 15 (0.00%)	5 / 45 (11.11%)	
occurrences (all)	0	6	
Reproductive system and breast disorders			
Heavy menstrual bleeding			

subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vaginal discharge			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Penile pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 15 (0.00%)	3 / 45 (6.67%)	
occurrences (all)	0	5	
Nasal congestion			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Dysphonia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
White blood cell count increased			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Platelet count increased			

subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Heart rate decreased subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Blood creatinine decreased subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Injury, poisoning and procedural complications			
Procedural pain subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Limb injury subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Cataract traumatic subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Animal bite subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Radius fracture subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Soft tissue injury subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	3 / 45 (6.67%) 3	
Wound			

subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Thermal burn subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Cardiac disorders Bradycardia subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	1 / 45 (2.22%) 1	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	8 / 15 (53.33%) 12	35 / 45 (77.78%) 77	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Presyncope subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	2 / 45 (4.44%) 3	
Dizziness subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	7 / 45 (15.56%) 7	
Loss of consciousness subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Syncope subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Blood and lymphatic system disorders Neutrophilia subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Monocytosis			

subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Lymphopenia subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Leukocytosis subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Ear and labyrinth disorders Cerumen impaction subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Ear pain subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Eye disorders Chalazion subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Photophobia subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Eye pain subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Vomiting subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Nausea			

subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Abdominal pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Toothache			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal sounds abnormal			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Hypoaesthesia oral			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hyperhidrosis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Pigmentation disorder			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	0 / 15 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Rash erythematous			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Urticaria			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	1 / 15 (6.67%)	2 / 45 (4.44%)	
occurrences (all)	1	2	

Erythema subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	3 / 45 (6.67%) 6	
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 45 (0.00%) 0	
Urethral discharge subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	8 / 15 (53.33%) 11	20 / 45 (44.44%) 37	
Pain in jaw subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Pain in extremity subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	1 / 45 (2.22%) 1	
Myalgia subjects affected / exposed occurrences (all)	6 / 15 (40.00%) 12	31 / 45 (68.89%) 60	
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Back pain subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1	0 / 45 (0.00%) 0	
Sacral pain subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0	0 / 45 (0.00%) 0	
Neck pain subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 2	1 / 45 (2.22%) 1	
Musculoskeletal pain			

subjects affected / exposed	1 / 15 (6.67%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Muscle swelling			
subjects affected / exposed	0 / 15 (0.00%)	3 / 45 (6.67%)	
occurrences (all)	0	4	
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
COVID-19			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Gastroenteritis			
subjects affected / exposed	1 / 15 (6.67%)	4 / 45 (8.89%)	
occurrences (all)	1	5	
Epididymitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Onychomycosis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract infection			
subjects affected / exposed	3 / 15 (20.00%)	8 / 45 (17.78%)	
occurrences (all)	5	8	
Sinusitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	

Pneumonia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Pharyngitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Urinary tract infection			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Acarodermatitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Body tinea			
subjects affected / exposed	1 / 15 (6.67%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Conjunctivitis			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Influenza			
subjects affected / exposed	2 / 15 (13.33%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Pelvic inflammatory disease			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tonsillitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tinea versicolour			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 15 (0.00%)	3 / 45 (6.67%)	
occurrences (all)	0	5	
Iron deficiency			

subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Dehydration			
subjects affected / exposed	0 / 15 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hypoglycaemia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 August 2022	The main reason for this amendment was to update the reporting duration of AEs/SAEs leading to withdrawal from the study and/or withholding doses of study intervention from up to the study end (Day 1 to Day 337) to 28 days after third study intervention administration (Day 1 to Day 197), a new secondary endpoint was added to include number of participants with AEs/SAEs leading to withdrawal from the study from 28 days after third study intervention administration (Day 197) up to Day 337 and the end of study information (in case where the end of study would be the date of last testing results revealed) was updated to be achieved no later than 8 months after last subject last visit instead of 6 months after third study intervention administration.
08 June 2023	The main reason for this amendment was to update tertiary endpoint related to seroresponse to improve the seroresponse endpoints and to optimize the number of samples to be tested from Stage 2 for functionality of antibodies, clarification was added on taking immunogenicity sample and safety follow-up for participant discontinued due to AE to avoid protocol deviations arising from taking immunogenicity samples from discontinued participants observed in Stage 1 due to lack of clarity and justification for collection of race (ethnic background) data was added.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported